- The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis
Kenneth Skov, Niels A. Graudal, Gesche Jürgens
Basic Clin. Pharmacol. Toxicol. 128, 568-578 (2021)
[DOI: 10.1111/bcpt.13553] [PDF]
296K 2024-04-18
- Notes on the Use of Kirchhoff's Laws in Pharmacokinetics
Ronald A. Siegel
AAPC J. 26, 8 (2024)
[DOI: 10.1208/s12248-024-00875-x] [PDF]
1.4M 2024-04-14
- Using Mechanistic Modeling Approaches to Support Bioequivalence Assessments for Oral Products
Fang Wu, Youssef Mousa, Rebeka Jereb, Hannah Batchelor, Sumon Chakraborty, Tycho Heimbach, Ethan Stier, Filippos Kesisoglou, Sivacharan Kollipara, Lei Zhang, Liang Zhao
AAPC J. 26, 19 (2024)
[DOI: 10.1208/s12248-024-00886-x] [PDF]
672K 2024-04-14
- An Explanation of Why Dose-Corrected Area Under the Curve for Alternate Administration Routes Can Be Greater than for Intravenous Dosing
Hirokazu Wakuda, Yue Xiang, Jasleen K. Sodhi, Naoto Uemura, Leslie Z. Benet
AAPC J. 26, 22 (2024)
[DOI: 10.1208/s12248-024-00887-w] [PDF]
896K 2024-04-12
- Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system
Wei Gong, Yan Liu, Dan-Yu Mei, Meiyan Yang, Xing-Guo Mei
Drug Dev. Ind. Pharm. 41, 464-469 (2015)
[DOI: 10.3109/03639045.2013.877923] [PDF]
504K 2024-04-12
- Population Pharmacokinetic Model of Human Insulin Following Different Routes of Administration
Elizabeth Potocka, Robert A. Baughman, and Hartmut Derendorf
J. Clin. Pharmacol. 51, 1015-1024 (2011)
[DOI: 10.1177/0091270010378520] [PDF]
388K 2024-03-16
- Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers
Mark Dershwitz, John L. Walsh, Richard J. Morishige, Patricia M. Connors, Reid M. Rubsamen, Steven L. Shafer, Carl E. Rosow
Anesthesiology 93, 619-628 (2000)
[DOI: 10.1097/00000542-200009000-00009] [PDF]
244K 2024-03-16
- Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
Heino Stass, Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Abhishek Gupta, Sybille Baumann
Clin. Drug Investig. 33, 419-427 (2013)
[DOI: 10.1007/s40261-013-0082-0] [PDF]
512K 2024-03-16
- Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs
Jens Markus Borghardt, Benjamin Weber, Alexander Staab, and Charlotte Kloft
AAPS J. 17, 853-870 (2015)
[DOI: 10.1208/s12248-015-9760-6] [PDF]
1.3M 2024-03-16
- FDA. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations (2014) [https://www.gmp-compliance.org/files/guidemgr/UCM389370.pdf] [also here]
808K 2024-02-24
- Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: bioequivalence of the new Sigmasporin Microoral and Sandimmun Neoral
Naji M. Najib, Nasir Idkaidek, Ayman Adel, B. Mohammed, Sahar Al-Masri, Isra' Admour, S. Mahmood Alam, Ruwayda Dham, Qumaruzaman
Eur. J. Pharm. Biopharm. 55, 67-70 (2003)
[DOI: 10.1016/S0939-6411(02)00157-1] [PDF]
100K 2024-01-26
- Safety assessment of Efavirenz after a single-dose bioequivalence study : a trend to correlate central nervous system effect and plasma concentrations
Marta Vázquez, Pietro Fagiolino, Manuel Ibarra, Laura Magallanes
Int. J. Pharm. 5, 46-52 (2015)
[https://www.pharmascholars.com/abstract/safety-assessment-of-efavirenz-after-a-singledose-bioequivalence-study-a-trend-to-correlate-central-nervous-system-effec-51194.html] [PDF]
540K 2024-01-06
- Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry by FDA/CDER/ Purdie, Florine P [also here]
164K 2024-01-04
- Solubility and Dissolution Rate Determination of Different Antiretroviral Drugs in Different pH Media Using UV Visible Spectrophotometer
K. Prakash, P. Narayana Raju , K. Shanta Kumari, and M. Lakshmi Narasu
E-Journal of Chemistry 5, 1159-1164 (2008)
[DOI: 10.1155/2008/125917] [PDF]
1.2M 2024-01-04
- Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations
J. C. Rotschafer, K. Crossley, D. E. Zaske, K. Mead, R. J. Sawchuk, L. D. Solem
Antimicrob. Agents Chemother. 22, 391-394 (1982)
[DOI: 10.1128/AAC.22.3.391] [PDF]
664K 2023-12-28
- Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function
Rashmi V. Shingde, Garry G. Graham, Stephanie E. Reuter, Jane E. Carland, Richard O. Day, Sophie L. Stocker
Ther. Drug Monit. 41, 726-731 (2019)
[DOI: 10.1097/FTD.0000000000000690] [PDF]
148K 2023-12-28
- TDM is dead. Long live TCI!
Nick Holford, Guangda Ma, David Metz
Br. J. Clin. Pharmacol. 88, 1406-1413 (2022)
[DOI: 10.1111//bcp.14434] [PDF]
712K 2023-12-27
- Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
Qingxia Liu, Huiping Huang, Baohua Xu, Dandan Li, Maobai Liu, Imam H. Shaik and Xuemei Wu
Pharmaceutics 14, 1004 (2022)
[DOI: 10.3390/pharmaceutics14051004] [PDF]
3.0M 2023-12-27
- Modifications of the Method for Calculating Absolute Drug Bioavailability
Wei Jiang, Juan-juan Yang, Lei Cao, Xue Xiao, Xiao-lian Shi, Yong-xiao Cao
J. Pharm. Pharm. Sci. 19, 181-187 (2016)
[DOI: 10.18433/J3RG78] [PDF]
388K 2023-12-07
- Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
José L. Calvo-Gallego, Peter Pivonka, Rocío Ruiz-Lozano and Javier Martinez-Reina
Front. Bioeng. Biotechnol. 10, 940620 (2022)
[DOI: 10.3389/fbioe.2022.940620] [PDF]
2.2M 2023-12-05
- The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women
Stefan Zajic, Stefaan Rossenu, David Hreniuk, Filippos Kesisoglou, Jacqueline McCrea, Fang Liu, Li Sun, Rose Witter, Don Gauthier, Roy Helmy, Darrick Joss, Tong Ni, Randall Stoltz, Julie Stone and S. Aubrey Stoch
Drug Metabolism and Disposition 44, 1450-1458 (2016)
[DOI: 10.1124/dmd.116.069906] [PDF]
700K 2023-12-04
- Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A. Suleiman, Sven Mensing, Anette Koenigsdorfer, Julia Teresa Schiele, Tammy Palenski, Divya Samineni, David Hoffman, Rajeev Menon & Ahmed Hamed Salem
Clin. Drug Investig. 42, 657-668 (2023)
[DOI: 10.1007/s40261-022-01172-4] [PDF]
1000K 2023-12-04
- An Alternative Approach for Assessment of Rate of Absorption in Bioequivalence Studies
Mei-Ling Chen
Pharm. Res. 9, 1380-1385 (1992)
[DOI: 10.1023/A:1015842425553] [PDF]
184K 2023-12-02
- Bioavailability of oral penicillins in the horse: a comparison of pivampicillin and amoxicillin
J. M. Ensink, W. R. Klein, D. J. Mevius, A. Klarenbeek, A. G. Vulto
Journal of Veterinary Pharmacology and Therapeutics 15, 221-230 (1992)
[DOI: 10.1111/j.1365-2885.1992.tb01010.x] [PDF]
696K 2023-12-01
- Use of area under the curve to estimate absolute bioavailability of digoxin
W. G. Kramer, R. H. Reuning
J. Pharm. Sci. 67, 141-142 (1978)
[DOI: 10.1002/jps.2600670145] [PDF]
216K 2023-11-30
- Factors Influencing the Selection of Medium for Evaluating Drug Solubility and Dissolution in Bovine Milk
Marilyn N. Martinez, David Longstaff, Vivek Fellner, and Martin Coffey
Dissolut. Technol. 30, 134-142 (2023)
[DOI: 10.14227/DT300323P134] [PDF]
496K 2023-11-30
- Steady-State Carbamazepine Pharmacokinetics Following Oral and Stable-Labeled Intravenous Administration in Epilepsy Patients: Effects of Race and Sex
S. E. Marino, A. K. Birnbaum, I. E. Leppik, J. M. Conway, L. C. Musib, R. C. Brundage, R. E. Ramsay, P. B. Pennell, J. R. White, C. R. Gross, J. O. Rarick, U. Mishra, J. C. Cloyd
Clin. Pharmacol. Therap. 91, 483-488 (2012)
[DOI: 10.1038/clpt.2011.251] [PDF]
192K 2023-11-20
- Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis
Paul Beringer, Kitty My Tu Huynh, Jane Kriengkauykiat, Luke Bi, Nils Hoem, Stan Louie, Emily Han, Thao Nguyen, Donald Hsu, Purush A. Rao, Bertrand Shapiro, and Mark Gill
Antimicrob. Agents Chemother. 49, 5013-5017 (2005)
[DOI: 10.1128/AAC.49.12.5013-5017.2005] [PDF]
92K 2023-11-20
- Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model
Chen Xu; Tanran Chang, Yaqi Du; Chaohui Yu, Xin Tan, Xiangdong Li
Env. Toxicol. Pharmacol. 70, 103202 (2019)
[DOI: 10.1016/j.etap.2019.103202] [PDF]
1.1M 2023-11-20
- Comparison of Dissolution Profiles and Apparent Permeabilities of Commercially Available Metformin Hydrochloride Tablets in Turkey
Yagmur Akdag, Tugba Gulsun, Nihan Izat, Levent Oner, and Selma Sahin
Dissolut. Technol. 27, 22-29 (2020)
[DOI: 10.14227/DT270120P22] [PDF]
752K 2023-11-18
- Dissolution Profiles of Three Brands of Lamivudine and Zidovudine Combinations in the Nigerian Market
N. A. Ochekpe, N. C. Ngwuluka, H. Owolayo, T. Fashedemi
Dissolut. Technol. 13, 12-17 (2006)
[DOI: 10.14227/DT130406P12] [PDF]
296K 2023-11-18
- In Vitro Dissolution Testing to Assess Pharmaceutical Equivalence of Selected Amoxicillin Products Available in Sri Lanka: A Post-Marketing Study
Dhanusha Thambavita, Charith M. Jayathilake, K. D. Darshi Sandamali, Priyadarshani Galappatthy, and Raveendra Laal Jayakody
Dissolut. Technol. 26, 56-61 (2019)
[DOI: 10.14227/DT260119P56] [PDF]
540K 2023-11-18
- Pharmaceutical Equivalence and Similarity Studies of Metoclopramide Tablets
Maria A. Varillas, Marta I.V. Brevedan, Noelia L. Gonzalez Vidal
Dissolut. Technol. 25, 14-21 (2018)
[DOI: 10.14227/DT250118P14] [PDF]
464K 2023-11-18
- Evaluation of In Vitro Equivalence for Drugs Containing BCS Class II Compound Ketoprofen
E. Shohin, J. I. Kulinich, G. V. Ramenskaya, and G. F. Vasilenko
Dissolut. Technol. 18, 26-29 (2011)
[DOI: 10.14227/DT180111P26] [PDF]
184K 2023-11-18
- Sitagliptin Phosphate: Development of a Dissolution Method for Coated Tablets Based on In Vivo Data for Improving Medium Sensitivity
Alini Dall Cortivo Lange, Ana Paula Batistel, Leticia Lenz Sfair, Jaison Carlosso, Nadia Maria Volpato, and Elfrides Eva Scherman Schapoval
Dissolut. Technol. 21, 17-22 (2014)
[DOI: 10.14227/DT210214P17] [PDF]
556K 2023-11-18
- Modeling of Particle Dissolution Behavior Using a Geometrical Phase-Field Approach
Dominik Sleziona, David R. Ely, and Markus Thommes
Molec. Pharmac. 19 3749-3756 (2022)
[DOI: 10.1021/acs.molpharmaceut.2c00214] [PDF]
3.2M 2023-11-18
- Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: Increasing the power of bioavailability tests
Henry d'A. Heck, Sidney E. Buttrill, Jr., Norman W. Flynn, Robert L. Dyer, Michael Anbar, Thomas Cairns, Shrikant Dighe, and Bernard E. Cabana
J. Pharmacokin. Biopharm. 7, 233-248 (1979)
[DOI: 10.1007/BF01060015] [PDF]
844K 2023-11-02
- Preclinical Bioavailability Assessment of a Poorly Water-Soluble Drug, HGR4113, Using a Stable Isotope Tracer
Eun Ji Ha, Jeong In Seo, Shaheed Ur Rehman, Hyung Soon Park, Sang-Ku Yoo and Hye Hyun Yoo
Pharmaceutics 15, 1684 (2023)
[DOI: 10.3390/pharmaceutics15061684] [PDF]
1.9M 2023-11-01
- Flip-flop pharmacokinetics delivering a reversal of disposition: challenges and opportunities during drug development
Jaime A Yanez, Connie M Remsberg, Casey L Sayre, M Laird Forrest & Neal M Davies
Therapeutic Delivery 2, 643-672 (2011)
[DOI: 10.4155/tde.11.19] [PDF]
1.1M 2023-10-03
- Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis
Carolina Ameijeiras Rodriguez, Sara Carolina Henriques, Aymara Sancho-Araiz, Inaki F. Troconiz, Luis Almeida, Nuno Elvas Silva
Pharm. Res. 38 2047-2063 (2021)
[DOI: 10.1007/s11095-021-03136-3] [PDF]
2.0M 2023-10-03
- Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS
Kimberly L. Garrison, Selma Sahin, Leslie Z. Benet
J. Pharm. Sci. 104, 3229-3235 (2015)
[DOI: 10.1002/jps.24505] [PDF]
128K 2023-09-25
- A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives
M.A. Nguyen, T. Flanagan, M. Brewster, F. Kesisoglou, S. Beato, J. Biewenga, J. Crison, R. Holm, R. Li, E. Mannaert, M. McAllister, M. Mueller-Zsigmondy, U. Muenster, K. Ojala, S. Page, A. Parr, S. Rossenu, P. Timmins, A. Van Peer, A. Vermeulen, P. Langguth
Eur. J. Pharm. Sci. 102, 1-13 (2017)
[DOI: 10.1016/j.ejps.2017.02.029] [PDF]
740K 2023-09-15
240K 2023-09-06
- Biphasic Dissolution as an Exploratory Method during Early Drug Product Development
Daniela Amaral Silva, Jozef Al-Gousous, Neal M. Davies, Nadia Bou Chacra, Gregory K. Webster, Elke Lipka, Gordon L. Amidon and Raimar Lobenberg
Pharmaceutics 12, 420 (2020)
[DOI: 10.3390/pharmaceutics12050420] [PDF]
2.7M 2023-08-27
- In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: A historical review
Aude Pestieau, Brigitte Evrard
Eur. J. Pharm. Sci. 102, 203-219 (2017)
[DOI: 10.1016/j.ejps.2017.03.019] [PDF]
1008K 2023-08-27
- In vitro models for the prediction of in vivo performance of oral dosage forms
Edmund S. Kostewicz, Bertil Abrahamsson, Marcus Brewster, Joachim Brouwers, James Butler, Sara Carlert, Paul A. Dickinson, Jennifer Dressman, Rene Holm, Sandra Klein, James Mann, Mark McAllister, Mans Minekus, Uwe Muenster, Anette Mullertz, Miriam Verwei, Maria Vertzoni, Werner Weitschies, Patrick Augustijns
Eur. J. Pharm. Sci. 57, 342-366 (2014)
[DOI: 10.1016/j.ejps.2013.08.024] [PDF]
1.9M 2023-08-27
- Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib
Shan Jiang, Guoqing Zhang, Lei Wang, Ye Zeng, Wenjie Liu, Zeneng Cheng
AAPS Pharm. Sci. Tech. 21, 59 (2020)
[DOI: 10.1208/s12249-019-1612-8] [PDF]
1004K 2023-08-27
- Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict
Gopal Pawar, Fang Wu, Liang Zhao, Lanyan Fang, Gilbert J. Burckart, Kairui Feng, Youssef M. Mousa, Abdullah Al Shoyaib, Marie-Christine Jones, Hannah K. Batchelor
AAPS J. 25, 67 (2023)
[DOI: 10.1208/s12248-023-00826-1] [PDF]
1.4M 2023-08-25
- Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation
I. Gonzalez-Garcia, A. Garcia-Arieta, M. Merino-Sanjuan, V. Mangas-Sanjuan, M. Bermejo
Eur. J. Pharm. Sci. 119, 200-207 (2018)
[DOI: 10.1016/j.ejps.2018.04.025] [PDF]
1.4M 2023-08-25
- Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics
Kazuko Sagawa, Jian Lin, Rohit Jaini, Li Di
Pharm. Res. 40, 1927-1938 (2023)
[DOI: 10.1007/s11095-023-03538-5] [PDF] [Supplementary Information]
1000K 2023-08-24
- Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine
Mauricio A. Garcia, Rodrigo Cristofoletti, Bertil Abrahamsson, Dirk W. Groot, Alan Parr, James E. Polli, Mehul Mehta, Vinod P. Shah, Tajiri Tomakazu, Jennifer B. Dressman, Peter Langguth
J. Pharm. Sci. 110 1935-1947 (2021)
[DOI: 10.1016/j.xphs.2021.02.019] [PDF]
744K 2023-08-23
- IVIVC approach based on carbamazepine bioequivalence studies combination
I. González-García, V. Mangas-Sanjuan, M. Merino-Sanjuán, C. Álvarez-Álvarez, J. Díaz-Garzón Marco, M. A. Rodríguez-Bonnín, T. Langguth, J. J. Torrado-Durán, P. Langguth, A. García-Arieta, M. Bermejo
Pharmazie 72, 449-457 (2017)
[DOI: 10.1691/ph.2017.7011] [PDF]
312K 2023-08-22
- Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patient
J Stangier, CAPF Su, and W Roth
J. Int. Med. Res. 28, 149-167 (2000)
[DOI: 10.1177/147323000002800401] [PDF]
88K 2023-08-21
- Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery
Mitesh Patel, Julia Riede, Dallas Bednarczyk, Birk Poller, Sujal V. Deshmukh
Pharm. Res. 40, 937-949 (2023)
[DOI: 10.1007/s11095-023-03482-4] [PDF] [Supplementary Information]
1.6M 2023-07-29
- EMA, CHMP: Guideline on the investigation of bioequivalence (2010) [also here]
236K 2023-07-28
- Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy
R. Hartley, J. Aleksandrowicz, C. J. Bowmer, A. Cawood, W. I. Forsythe
J. Pharm. Pharmacol. 43, 117-119 (1991)
[DOI: 10.1111/j.2042-7158.1991.tb06644.x] [PDF]
296K 2023-07-17
- ICH Reflection paper on proposed international harmonisation of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of medicines
EMA Committee for Human Medicinal Products
[EMA] [PDF] [Comments]
392K 2023-07-16
- Metformin doses to ensure efficacy and safety in patients with reduced kidney function
Isabelle H. S. Kuan, Luke C. Wilson, Jed C. Leishman, Samuel Cosgrove, Robert J. Walker, Tracey L. Putt, John B. W. Schollum, Daniel F. B. Wright
PLoS ONE 16, e0246247 (2021)
[DOI: 10.1371/journal.pone.0246247] [PDF]
728K 2023-07-15
- Metformin kinetics in healthy subjects and in patients with diabetes mellitus
G.T. Tucker, C. Casey, P.J. Phillips, H. Connor, J.D. Ward & H.F. Woods
Br. J. Clin. Pharmacol. 12, 235-246 (1981)
[DOI: 10.1111/j.1365-2125.1981.tb01206.x] [PDF]
1.3M 2023-07-15
- The influence of flip-flop in population pharmacokinetic analyses
Isabelle H. S. Kuan, Daniel F. B. Wright, Stephen B. Duffull
CPT Pharmacometrics Syst. Pharmacol. 12, 285-287 (2023)
[DOI: 10.1002/psp4.12909] [PDF]
240K 2023-07-15
- Zero-order drug delivery: State of the art and future prospects
Mei-Li Laracuentea, Marina H. Yua, Kevin J. McHugha
J. Control. Release 327, 834-856 (2020)
[DOI: 10.1016/j.jconrel.2020.09.020] [PDF]
5.9M 2023-07-08
- In vitro dissolution as a tool for formulation selection: Telmisartan two-step IVIVC
Alejandro Ruiz-Picazo, Ma Teresa Martinez-Martinez, Sarin Colon-Useche, Ramon Iriarte, Barbara Sanchez-Dengra, Marta Gonzalez-Alvarez, Alfredo Garcia-Arieta, Isabel Gonzalez Alvarez, and Marival Bermejo
Mol. Pharmaceutics 15, 2307-2315 (2018)
[DOI: 10.1021/acs.molpharmaceut.8b00153] [PDF]
2.8M 2023-06-06
- From Camille Nούς to Apollonian and the Dionysian scientists
Panos Macheras, Caitlin Di Paolo, Yanna Pusica and Eleftherios P. Diamandis
Diagnosis 9, 1-2 (2022)
[DOI: 10.1515/dx-2021-0057] [PDF]
404K 2023-06-03
- Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach
Jean Michel Cardot, John C Lukas, Paula Muniz
AAPS J. 20, 95 (2018)
[DOI: 10.1208/s12248-018-0250-5] [PDF]
1004K 2023-06-03
- A novel method to estimate the absorption rate constant for two-compartment model fitted drugs without intravenous pharmacokinetic data
Fan Liu, Hanxi Yi, Lei Wang, Zeneng Cheng, Guoqing Zhang
Front. Pharmacol. 14, (2023)
[DOI: 10.3389/fphar.2023.1087913] [PDF]
2.8M 2023-06-03
- In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature
Sherin Thomas, Dana C. Hammell, Hazem E. Hassan, Audra L. Stinchcomb
Pharm. Res. 40, 1249-1258 (2023)
[DOI: 10.1007/s11095-023-03487-z] [PDF]
872K 2023-06-01
- The absorption of adrenalin
D. Murray Lyon
J. Exp. Med. 38, 655-665 (1923)
[DOI: 10.1084/jem.38.6.655] [PDF]
516K 2023-05-29
- Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study
Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen, Sissel Skarra, Ola Dale
Tidsskr. Nor. Laegeforen. 139, (13) (2019)
[DOI: 10.4045/tidsskr.19.0162] [PDF]
236K 2023-05-07
748K 2023-05-07
- Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs
Brandon M. Wahler, Phillip Lerche, Carolina H. Ricco Pereira, Richard M. Bednarski, Butch KuKanich, Jeffrey Lakritz, and Turi K. Aarnes
Am. J. Vet. Res. 80, 696-701 (2019)
[DOI: 10.2460/ajvr.80.7.696] [PDF]
268K 2023-05-07
- Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal
Gill Mundin, Rebecca McDonald, Kevin Smith, Stephen Harris, John Strang
Addiction 112, 1647-1652 (2017)
[DOI: 10.1111/add.13849] [PDF]
420K 2023-05-05
- Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers
E. Vanky, L. Hellmundt, U. Bondesson, S. Eksborg and S. Lundeberg
Acta Anaesthesiologica Scandinavica 61, 636-640 (2017)
[DOI: 10.1111/aas.12898] [PDF]
172K 2023-05-05
- Rapid systemic uptake of naloxone after intranasal administration in children
Eva Malmros Olsson, Per-Arne Lonnqvist, Carl-Olav Stiller, Staffan Eksborg, Stefan Lundeberg
Pediatric Anesthesia 00, 1-6 (2021)
[DOI: 10.1111/pan.14175] [PDF]
300K 2023-05-05
- International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database
Rebecca McDonald, Oyvind Danielsson Glende, Ola Dale, John Strang
Drug Alcohol Rev. 37, 205-215 (2017)
[DOI: 10.1111/dar.12571] [PDF]
620K 2023-05-05
- A Novel faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
Tair Lapidot, Mohammed Bouhajib, Janice Faulknor, Shabaz Khan, Galia Temtsin Krayz, Carolina Abrutzky, Dalia Megiddo
Pharm. Res. 39, 963-975 (2022)
[DOI: 10.1007/s11095-022-03247-5] [PDF]
1.5M 2023-05-05
- Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies
BT Gufford, GR Ainslie, JR White Jr, ME Layton, JM Padowski, GM Pollack and MF Paine
Clin. Transl. Sci. 10, 380-386 (2017)
[DOI: 10.1111/cts.12473] [PDF]
88K 2023-05-05
- Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products
Roberto Gomeni & Francoise Bressolle-Gomeni
J. Pharmacokin. Pharmacodyn. 50, 89-96 (2023)
[DOI: 10.1007/s10928-022-09835-7] [PDF]
1.2M 2023-05-01
- Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Jennifer E. Sager, Jingjing Yu, Isabelle Ragueneau-Majlessi, and Nina Isoherranen
Drug Metab. Disp. 43, 1823-1837 (2015)
[DOI: 10.1124/dmd.115.065920] [PDF]
508K 2023-04-30
- FDA Guidance for Industry. Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations
Venkata Ramana Uppoor et al.
Dissolut. Technol. 4, 23-32 (1997)
[DOI: 10.14227/DT040497P23] [PDF]
3.2M 2023-04-30
- Numerical deconvolution by least squares: use of prescribed input functions
David J. Cutler
J. Pharmacokin. Biopharm. 6, 227-241 (1978)
[DOI: 10.1007/BF01312264] [PDF]
672K 2023-04-26
- Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug
John G. Wagner, Eino Nelson
J. Pharm. Sci. 53, 1392-1403 (1964)
[DOI: 10.1002/jps.2600531126] [PDF]
972K 2023-04-26
- Influence of diet and fluid on bioavailability of theophylline
P. G. Welling, L. L. Lyons, W. A. Craig, G. A. Trochta
Clin. Pharmacol. Therap. 17, 475-480 (1975)
[DOI: 10.1002/cpt1975174475] [PDF]
764K 2023-04-18
- Noncompartmental Determination of the Steady-State Volume of Distribution
Leslie Z. Benet, Renato L. Galeazzi
J. Pharm. Sci. 68, 1071-1074 (1979)
[DOI: 10.1002/jps.2600680845] [PDF]
476K 2023-04-18
612K 2023-04-18
- Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
Win L. Chiou
J. Pharmacokin. Biopharm. 6, 539-546 (1978)
[DOI: 10.1007/BF01062108] [PDF]
420K 2023-04-18
- The Uses and Advantages of Kirchhoff's Laws vs. Differential Equations in Pharmacology, Pharmacokinetics, and (Even) Chemistry
Leslie Z. Benet, Jasleen K. Sodhi
AAPS J. 25, 38 (2023)
[DOI: 10.1208/s12248-023-00801-w] [PDF]
1.2M 2023-04-16
- Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly
Sarina Tanimoto, Michael Kaliner, Richard F. Lockey, Motohiro Ebisawa, Luana Pesco Koplowitz, Barry Koplowitz, Richard Lowenthal
Ann. Allergy Asthma Immunol. 130, 508-514 (2023)
[DOI: 10.1016/j.anai.2022.10.024] [PDF]
1.8M 2023-04-06
- Flucytosine kinetics in subjects with normal and impaired renal function
Ralph E. Cutler, Andrew D. Blair, Michael R. Kelly
Clin. Pharmacol. Therap. 24, 333-342 (1978)
[DOI: 10.1002/cpt1978243333] [PDF]
752K 2023-03-28
- Clinical Pharmacokinetics of Systemic Antifungal Drugs
T. K. Daneshmend & D. W. Warnock
Clin. Pharmacokin. 8, 17-42 (1983)
[DOI: 10.2165/00003088-198308010-00002] [PDF]
2.1M 2023-03-28
- Estimating and Assessing Differential Equation Models with Time-Course Data
Samuel W. K. Wong, Shihao Yang, and S. C. Kou
J. Phys. Chem. B 127, 2362-2374 (2023)
[DOI: 10.1021/acs.jpcb.2c08932] [PDF] [Supporting Information]
1.5M 2023-03-23
- Estimating and Assessing Differential Equation Models with Time-Course Data
Samuel W. K. Wong, Shihao Yang, and S. C. Kou
J. Phys. Chem. B 127, 2362-2374 (2023)
[DOI: 10.1021/acs.jpcb.2c08932] [PDF] [Supporting Information]
5.7M 2023-03-23
- EMA ICH M9 guideline on biopharmaceutics classification system-based biowaivers Step 5 [also here]
364K 2023-03-15
- Transdermal patches: history, development and pharmacology
Michael N. Pastore, Yogeshvar N. Kalia, Michael Horstmann and Michael S. Roberts
Br. J. Pharmacol. 172, 22179-2209 (2015)
[DOI: 10.1111/bph.13059] [PDF]
2.9M 2023-03-08
treatment function and fuzzy transmission
N. P. Dong, H. V. Long and N. T. K. Son
Iranian J. Fuzzy Systems 20, 1-18 (2023)
[DOI: 10.22111/IJFS.2023.7342] [PDF]
720K 2023-03-08
- Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs
H. Kortejärvi, R. Shawahna, A. Koski, J. Malkki, K. Ojala, M. Yliperttula
J. Pharm. Sci. 99, 621-625 (2010)
[DOI: 10.1002/jps.21879] [PDF]
136K 2023-03-07
- Release and absorption rate aspects of intramuscularly injected pharmaceuticals
J. Zuidema, F.A.J.M. Pieters and G.S.M.J.E. Duchateau
Int. J. Pharm. 47, 1-12 (1988)
[DOI: 10.1016/0378-5173(88)90209-8] [PDF]
864K 2023-02-12
- Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Jarkko Johansson, Jussi Hirvonen, Zsofia Lovro, Laura Ekblad, Valtteri Kaasinen, Olli Rajasilta, Semi Helin, Jouni Tuisku, Saija Siren, Mirka Pennanen, Arvind Agrawal, Roger Crystal, Petri J. Vainio, Hannu Alho & Mika Scheinin
Neuropsychopharmacology 44, 1667-1673 (2019)
[DOI: 10.1038/s41386-019-0368-x] [PDF]
1.1M 2023-02-12
- Papers and patents are becoming less disruptive over time
Michael Park, Erin Leahey, Russell J. Funk
Nature 613, 138-144 (2023)
[DOI: 10.1038/s41586-022-05543-x] [PDF]
4.8M 2023-01-12
- An Analytical Solution for Saturable Absorption in Pharmacokinetics Models
C.O.S. Sorzano, M.A. Perez-de-la-Cruz Moreno, J.L. Vilas
Pharm. Res. 39, (2022)
[DOI: 10.1007/s11095-022-03455-z] [PDF]
548K 2023-01-11
- A compartmental absorption and transit model for estimating oral drug absorption
Lawrence X. Yu, Gordon L. Amidon
Int. J. Pharm. 186, 119-125 (1999)
[DOI: 10.1016/s0378-5173(99)00147-7] [PDF]
108K 2022-12-28
- PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective
Cordula Stillhart, Xavier Pepin, Christophe Tistaert, David Good, An Bergh, Neil Parrott, Filippos Kesisoglou
AAPS J. 21, 19 (2019)
[DOI: 10.1208/s12248-019-0292-3] [PDF]
2.0M 2022-12-28
- Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
Louis Lin and Harvey Wong
Pharmaceutics 9, 41 (2017)
[DOI: 10.3390/pharmaceutics9040041] [PDF]
1.6M 2022-12-28
- Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products
Gopal Pawar, Fang Wu, Liang Zhao, Lanyan Fang, Gilbert J. Burckart, Kairui Feng, Youssef M. Mousa, Franci Naumann, Hannah K. Batchelor
AAPS J. 23, 57 (2021)
[DOI: 10.1208/s12248-021-00592-y] [PDF]
552K 2022-12-11
- Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods
Roberto Gomeni, Francoise Bressolle-Gomeni
AAPS J. 22, 67 (2020)
[DOI: 10.1208/s12248-020-00445-0] [PDF]
788K 2022-12-11
- Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study
Disala Fernando, Sarah Siederer, Sunita Singh, Ian Schneider, Ashutosh Gupta, Marcy Powell, Duncan Richards, Michelle P. McIntosh, Peter Lambert, Susan Fowles
EBioMedicine 22, 249-255 (2017)
[DOI: 10.1016/j.ebiom.2017.07.020] [PDF]
540K 2022-12-03
- Absolute Bioavailability of Oral Theophylline
Leslie Hendeles, Miles Weinberger and Lyle Bighley
Am. J. Hosp. Pharm. 34, 525-527 (1977)
[DOI: 10.1093/ajhp/34.5.525] [PDF]
336K 2022-11-27
- Comparative bioavailability of a new sustained-release theophylline tablet
Kenzo Takagi, Takako Watanabe, Tatsuo Satake, Takaaki Hasegawa, Yozo Ogura, Norishige Imaeda, Yuzo Mizukami
Jpn. J. Allergol. 36, 1006-1011 (1987)
[DOI: 10.15036/arerugi.36.1006] [PDF]
696K 2022-11-27
- Sustained Release Theophylline Preparations Practical Recommendations for Prescribing and Therapeutic Drug Monitoring
Anne Glynn-Barnhart, Malcolm Hill and Stanley J. Szejler
Drugs 35, 711-726 (1988)
[DOI: 10.2165/00003495-198835060-00006] [PDF]
2.5M 2022-11-27
- Brief Report: Poor Bioavailability of Sustained-Release Theophylline. A Case for Liquid Theophylline
Jonathan Corren, Anne Glynn-Barnhart
J. Asthma 28, 57-60 (1991)
[DOI: 10.3109/02770909109073372] [PDF]
400K 2022-11-26
- The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets
W. W. Arkinstall, M. Hopkinson, R. N. Rivington, L. Calcutt, T. Aitken, and J. H. Stewart
J. Allergy Clin. Immun. 82, 155-164 (1988)
[DOI: 10.1016/0091-6749(88)90994-3] [PDF]
1.1M 2022-11-26
- Sustained-release theophylline preparations: Comment on "The clinical significance of food-induced changes in the absorption of theophylline from Uniphyl tablets"
Miles M. Weinberger
J. Allergy Clin. Immun. 85, 530 (1990)
[DOI: 10.1016/0091-6749(90)90171-Y] [PDF]
- Reply to "Sustained-release theophylline preparations"
Mark S. Dykewicz, Roy Patterson, Carol A. Wiggins
J. Allergy Clin. Immun. 85, 530-531 (1990)
[DOI: 10.1016/0091-6749(90)90172-Z] [PDF]
244K 2022-11-26
- Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats
Tomoyuki Furubayashi, Akiko Kamaguchi, Kazushi Kawaharada, Yoshie Masaoka, Makoto Kataoka, Shinji Yamashita, Yutaka Higashi, Toshiyasu Sakane
Biol. Pharm. Bull. 30, 608-611 (2007)
[DOI: 10.1248/bpb.30.608] [PDF]
196K 2022-11-22
- Influence of electrostatic heteroaggregation of lipid droplets on their stability and digestibility under simulated gastrointestinal conditions
Yingyi Mao and David Julian McClements
Food Funct. 3, 1025-1034 (2012)
[DOI: 10.1039/c2fo30108c] [PDF]
852K 2022-11-22
- Pharmacokinetics and Metabolism of Transdermal Oxybutynin In Vitro and in Vivo Performance of a Novel Delivery System
R. Howard Zobrist, Danyi Quan, Heather M. Thomas, Stephanie Stanworth, and Steven W. Sanders
Pharm. Res. 20, 103-109 (2003)
[DOI: 10.1023/A:1022259011052] [PDF]
96K 2022-11-14
- Pharmacokinetics of Methylphenidate After Oral Administration of Two Modified-Release Formulations in Healthy Adults
John S. Markowitz, Arthur B. Straughn, Kennerly S. Patrick, C. Lindsay DeVane, Linda Pestreich, James Lee, Yanfeng Wang & Rafael Muniz
Clin. Pharmacokinet. 42, 393-401 (2003)
[DOI: 10.2165/00003088-200342040-00007] [PDF]
144K 2022-11-12
- The pharmacokinetics of oxybutynin in man
J. Douchamps, F. Derenne, A. Stockis, D. Gangji, M. Juvent & A. Herchuelz
Eur. J. Clin. Pharmacol. 35, 515-520 (1988)
[DOI: 10.1007/BF00558247] [PDF]
672K 2022-10-26
- Physiologically-based pharmacokinetic simulations in pharmacotherapy: selection of the optimal administration route for exogenous melatonin
Adriana Savoca, Davide Manca
ADMET & DMPK 7, 44-59 (2019)
[DOI: 10.5599/admet.625] [PDF]
1.3M 2022-10-20
- Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation?
Mahmoud Azzeh, Marco Battaglia, Simon Davies, John Strauss, Prashant Dogra, Venkata Yellepeddi
Int. J. Clin. Pharmacol. Ther. 60, 253-263 (2022)
[DOI: 10.5414/CP204217] [PDF] [Supplementary Information]
1.9M 2022-10-19
- Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation?
Mahmoud Azzeh, Marco Battaglia, Simon Davies, John Strauss, Prashant Dogra, Venkata Yellepeddi
Int. J. Clin. Pharmacol. Ther. 60, 253-263 (2022)
[DOI: 10.5414/CP204217] [PDF] [Supplementary Information]
1000K 2022-10-19
- Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS ® Formulation of Oxybutynin
Andres Olivares-Morales, Avijit Ghosh, Leon Aarons, Amin Rostami-Hodjegan
AAPS J. 18, 1532 (2016)
[DOI: 10.1208/s12248-016-9965-3] [PDF]
1.7M 2022-10-17
- One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products
Mercedes Prieto-Escolar, Juan J. Torrado, Covadonga Alvarez, Alejandro Ruiz-Picazo, Marta Simon-Vazquez, Carlos Govantes, Jesus Frias, Alfredo Garcia-Arieta, Isabel Gonzalez-Alvarez and Marival Bermejo
Pharmaceutics 13, 690 (2021)
[DOI: 10.3390/pharmaceutics13050690] [PDF]
5.9M 2022-10-16
- Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen
I. Camara-Martinez, J.A. Blechar, A. Ruiz-Picazo, A. Garcia-Arieta, C. Calandria, V. Merino-Sanjuan, P. Langguth, M. Gonzalez-Alvarez, M. Bermejo, J. Al-Gousous, I. Gonzalez-Alvarez
Int. J. Pharm. 614, 121415 (2022)
[DOI: 10.1016/j.ijpharm.2021.121415] [PDF]
820K 2022-10-16
1.2M 2022-10-16
- In Vitro-In Vivo Correlation Strategy Applied to an Immediate-Release Solid Oral Dosage Form with a Biopharmaceutical Classification System IV Compound Case Study
Gerard M. Bredael, Niya Bowers, Fabien Boulineau, David Hahn
J. Pharm. Sci. 103, 2125-2130 (2014)
[DOI: 10.1002/jps.24036] [PDF]
1.9M 2022-10-16
- Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls
Filippos Kesisoglou, Andre Hermans, Colleen Neu, Ka Lai Yee, John Palcza, Jessica Miller
J. Pharm. Sci. 104, 2913-2922 (2015)
[DOI: 10.1002/jps.24362] [PDF]
540K 2022-10-16
- Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation
Rajendar K. Mittapalli, Silpa Nuthalapati, Alyssa E. Delke DeBord, Hao Xiong
Pharm. Res. 34, 1187-1192 (2017)
[DOI: 10.1007/s11095-017-2133-3] [PDF]
844K 2022-10-16
- Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
Mohamed-Eslam F. Mohamed, Sheryl Trueman, Ahmed A. Othman, Jian-Hwa Han, Tzuchi R. Ju, Patrick Marroum
AAPS J. 21, 108 (2019)
[DOI: 10.1208/s12248-019-0378-y] [PDF]
992K 2022-10-16
- Development of In Vitro-In Vivo Correlation for Extended Release Niacin After Administration of Hypromellose Based Matrix Formulations to Healthy Volunteers
Filippos Kesisoglou, Stefaan Rossenu, Colm Farrell, Michiel van den Heuvel, Marita Prohn, Shaun Fitzpatrick, Pieter-Jan de Kam, Ryan Vargo
J. Pharm. Sci. 103, 3713-3723 (2014)
[DOI: 10.1002/jps.24179] [PDF]
872K 2022-10-16
- Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate
Filippos Kesisoglou, Binfeng Xia, and Nancy G. B. Agrawal
AAPS J. 17, 1492-1500 (2015)
[DOI: 10.1208/s12248-015-9816-7] [PDF]
748K 2022-10-16
- Single- and Multiple-Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase-2, in Man
Nancy G. B. Agrawal, Arturo G. Porras, Catherine Z. Matthews, Mark J. Rose, Eric J. Woolf, Bret J. Musser, Andrea L. Dynder, Katherine E. Mazina, Kenneth C. Lasseter, Thomas L. Hunt, Jules I. Schwartz, Jacqueline B. McCrea, Keith M. Gottesdiener
J. Clin. Pharmacol. 43, 268-276 (2013)
[DOI: 10.1177/0091270003251122] [PDF]
128K 2022-10-16
- A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
G. Krishna, L. Ma, M.Martinho, R. A. Preston and E. O'Mara
J. Antimicrob. Chemother. 67, 2725-2730 (2012)
[DOI: 10.1093/jac/dks268] [PDF]
244K 2022-10-16
- Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults
Rachel Courtney, Sudhakar Pai, Mark Laughlin, Josephine Lim, and Vijay Batra
J. Antimicrob. Chemother. 47, 2788-2795 (2003)
[DOI: 10.1128/AAC.47.9.2788-2795.2003] [PDF]
148K 2022-10-16
- A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/ Elbasvir in Healthy Chinese Participants
Haiyan Li, Zhenhua Yang, Shuang Zhang, Lin Xu, Yudong Wei, Jun Jiang, Luzelena Caro, Hwa-Ping Feng, Jacqueline B McCrea, Meng Li, Shuang Xie, Jiangdian Wang, Xu Min Zhao, Shengmei Mu
Clin. Pharmacol. 12, 1-11 (2020)
[DOI: 10.2147/CPAA.S224662] [PDF]
6.3M 2022-10-16
- Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men
Ka Lai Yee, Jacqueline McCrea, Deborah Panebianco, Wen Liu, Nicole Lewis, Tamara Cabalu, Steven Ramael, Rebecca E. Wrishko
Clin. Drug Investig. 38, 631-638 (2018)
[DOI: 10.1007/s40261-018-0650-4] [PDF]
492K 2022-10-16
- Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics - results from single oral dose studies in healthy volunteers
S. Aubrey Stoch, Stefan Zajic, Julie A. Stone, Deborah L. Miller, Lucas van Bortel, Kenneth C. Lasseter, Barnali Pramanik, Caroline Cilissen, Qi Liu, Lida Liu, Boyd B. Scott, Deborah Panebianco, Yu Ding, Keith Gottesdiener & John A. Wagner
Br. J. Clin. Pharmacol. 75, 1240-1254 (2012)
[DOI: 10.1111/j.1365-2125.2012.04471.x] [PDF]
2.9M 2022-10-16
- Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action
S. H. Ngai, Barry A. Berkowitz, J. C. Yang, James Hempstead, Sydney Spector
Anesthesiology 44, 398-401 (1976)
[DOI: 10.1097/00000542-197605000-00008] [PDF]
200K 2022-10-12
- A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
Julie Crockett, David Critchley, Bola Tayo, Joris Berwaerts, Gilmour Morrison
Epilepsia 61, 267-277 (2020)
[DOI: 10.1111/epi.16419] [PDF]
796K 2022-10-09
- Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs
Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke A. Wittenburg
Can. J. Vet. Res. 82, 178-183 (2018)
[PMCID: PMC6038833] [PDF]
1.8M 2022-10-08
- Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol
Aleksandra Zielinska, Amanda Cano, Tatiana Andreani, Carlos Martins-Gomes, Amelia M. Silva, Marlena Szalata, Ryszard Slomski and Eliana B. Souto
Int. J. Mol. Sci. 23, 6165 (2022)
[DOI: 10.3390/ijms23116165] [PDF]
2.5M 2022-10-08
- A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog
Yael Shilo-Benjamini, Ahuva Cern, Daniel Zilbersheid, Atara Hod, Eran Lavy, Dinorah Barasch and Yechezkel Barenholz
Front. Vet. Sci. 9, 892306 (2022)
[DOI: 10.3389/fvets.2022.892306] [PDF]
452K 2022-10-08
- Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption_ An UNGAP review
Maria Vertzoni, Patrick Augustijns, Michael Grimm, Mirko Koziolek, Glenn Lemmens, Neil Parrott, Christina Pentafragka, Christos Reppas, Jari Rubbens, Jens Van Den Αbeele, Tim Vanuytsel, Werner Weitschies, Clive G. Wilson
Eur. J. Pharm. Sci. 134, 153-175 (2019)
[DOI: 10.1016/j.ejps.2019.04.013] [PDF]
2.4M 2022-10-04
- The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group
Mirko Koziolek, Stefano Alcaro, Patrick Augustijns, Abdul W. Basit, Michael Grimm, Bart Hens, Caroline L. Hoad, Philipp Jedamzik, Christine M. Madla, Marc Maliepaard, Luca Marciani, Annalisa Maruca, Neil Parrott, Petr Pavek, Christopher J.H. Porter, Christos Reppas, Diana van Riet-Nales, Jari Rubbens, Marina Statelova, Natalie L. Trevaskis, Katerina Valentova, Maria Vertzoni, Dubravka Vitali Cepo, Maura Corsetti
Eur. J. Pharm. Sci. 134, 31-59 (2019)
[DOI: 10.1016/j.ejps.2019.04.003] [PDF]
4.0M 2022-10-04
- A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O'Sullivan
Front. Pharmacol. 9, 1365 (2018)
[DOI: 10.3389/fphar.2018.01365] [PDF]
900K 2022-10-04
2.3M 2022-10-04
- Inclusion complexes of cannabidiol with β-cyclodextrin and its derivative: Physicochemical properties, water solubility, and antioxidant activity
Hang Li, Sen-Lin Chang, Tan-Ran Chang, Ying You, Xiao-Dong Wang, Li-Wei Wang, Xiao-Fan Yuan, Ming-Hui Tan, Pei-Dong Wang, Peng-Wei Xu, Wei-Bo Gao, Qing-Sheng Zhao, Bing Zhao
J. Molec. Liquids 334, 116070 (2021)
[DOI: 10.1016/j.molliq.2021.116070] [PDF]
1.9M 2022-10-02
- Evzio (naloxone hydrochloride injection) Auto-injector for intramuscular or subcutaneous use
FDA , 4001455 (2016)
[DOI: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209862lbl.pdf] [PDF]
1.2M 2022-09-22
816K 2022-09-21
- A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia
Adriaan Cleton, Stefaan Rossenu, Herta Crauwels, Joris Berwaerts, David Hough, Srihari Gopal, Marielle Eerdekens, An Vandebosch, Bart Remmerie, Marc De Meulder, and Clara M. Rosso
J. Clin. Pharmacol. 54, 1048-1057 (2014)
[DOI: 10.1002/jcph.295] [PDF]
588K 2022-09-19
- Physiological Parameters for Oral Delivery and in Vitro Testing
Deanna M. Mudie, Gordon L. Amidon, and Gregory E. Amidon
Mol. Pharm. 7, 1388-1405 (2010)
[DOI: 10.1021/mp100149j] [PDF]
852K 2022-09-17
- Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State
Deanna M. Mudie, Kathryn Murray, Caroline L. Hoad, Susan E. Pritchard, Martin C. Garnett, Gordon L. Amidon, Penny A. Gowland, Robin C. Spiller, Gregory E. Amidon, and Luca Marciani
Mol. Pharm. 11, 3039-3047 (2014)
[DOI: 10.1021/mp500210c] [PDF]
1.6M 2022-09-17
- Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations
Nina Brvar, Tatjana Mateovic-Rojnik, Iztok Grabnar
Int. J. Pharm. 473, 170-178 (2014)
[DOI: 10.1016/j.ijpharm.2014.07.013] [PDF]
1.3M 2022-09-17
- Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects
Thierry Wendling, Kayode Ogungbenro, Etienne Pigeolet, Swati Dumitras, Ralph Woessner & Leon Aarons
Pharm. Res. 32, 1764-1778 (2015)
[DOI: 10.1007/s11095-014-1574-1] [PDF]
1.1M 2022-09-04
- Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device
Philip A. Krieter, Nora Chiang, Shwe Gyaw, and David J. McCann
J. Clin. Pharmacol. 59, 1078-1084 (2019)
[DOI: 10.1002/jcph.1401] [PDF]
240K 2022-08-20
- Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles
Honghui Zhou
J. Clin. Pharmacol. 43, 211-227 (2003)
[DOI: 10.1177/0091270002250613] [PDF]
988K 2022-08-15
- Mixed Effect Modeling of Sumatriptan Pharmacokinetics During Drug Development: II. From Healthy Subjects to Phase 2 Dose Ranging in Patients
Valerie F. Cosson & Eliane Fuseau
J. Pharmacokin and Biopharmac. 27, 149-171 (1999)
[DOI: 10.1023/a:1020601906027] [PDF]
1.6M 2022-08-06
- Clinical Pharmacokinetics of the Salicylates
Christopher J. Needs & P. M. Brooks
Clin. Pharmacokin. 10, 164-177 (1985)
[DOI: 10.2165/00003088-198510020-00004] [PDF]
1.5M 2022-08-06
- Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose - a randomized controlled trial
Arne Kristian Skulberg, Anders Asberg, Hasse Zare Khiabani, Hilde Rostad, Ida Tylleskar, Ola Dale
Addiction 114, 859-867 (2019)
[DOI: 10.1111/add.14552] [PDF]
444K 2022-07-25
- Pharmacokinetics of a new, nasal formulation of naloxone
Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen, Sissel Skarra, Phatsawee Jansook & Ola Dale
Eur. J. Clin. Pharmacol. 73, 555-562 (2017)
[DOI: 10.1007/s00228-016-2191-1] [PDF]
472K 2022-07-25
- Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers
Arne Kristian Skulberg, Ida Tylleskar, Turid Nilsen, Sissel Skarra, Oyvind Salvesen, Trond Sand, Thorsteinn Loftsson & Ola Dale
Eur. J. Clin. Pharmacol. 74, 873-883 (2018)
[DOI: 10.1007/s00228-018-2443-3] [PDF]
1.6M 2022-07-25
- Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose
Philip Krieter, Nora Chiang, Shwe Gyaw, Phil Skolnick, Roger Crystal, Fintan Keegan, Julie Aker, Melissa Beck, and Jennifer Harris
J. Clin. Pharmacol. 56, 1243-1253 (2016)
[DOI: 10.1002/jcph.759] [PDF]
584K 2022-07-25
- Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers
Jonathonm Dowling, Geoffrey K. Isbister, Carl M. J. Kirkpatrick, Daya Naidoo, and Andis Graudins
Ther. Drug Monit. 30, 490-496 (2008)
[DOI: 10.1097/FTD.0b013e3181816214] [PDF]
264K 2022-07-25
- Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial
Paul Dietze, Marianne Jauncey, Allison Salmon, Mohammadreza Mohebbi, Julie Latimer, Ingrid van Beek, Colette McGrath, Debra Kerr
JAMA Network Open 2, e1914977 (2019)
[DOI: 10.1001/jamanetworkopen.2019.14977] [PDF]
928K 2022-07-25
- Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study
Rebecca McDonald, Ulrike Lorch, Jo Woodward, Bjorn Bosse, Helen Dooner, Gill Mundin, Kevin Smith, John Strang
Addiction 113, 484-493 (2018)
[DOI: 10.1111/add.14033] [PDF]
648K 2022-07-25
- INTRAV and ORAL: BASIC interactive computer programs for estimating pharmacokinetic parameters
J. L. Valentine and Samuel Hunter
J. Pharm. Sci. 74, 113-119 (1985)
[DOI: 10.1002/jps.2600740202] [PDF]
672K 2022-07-24
- Interpretation of area under the curve measurements for drugs subject to enterohepatic cycling
Theresa A. Shepard, Richard H. Reuning, Leon J. Aarons
J. Pharm. Sci. 74, 227-228 (1985)
[DOI: 10.1002/jps.2600740228] [PDF]
220K 2022-07-24
- Time in review (editorial)
Sharon D. Boots
J. Pharm. Sci. 75, 1017 (1986)
[DOI: 10.1002/jps.2600751102] [PDF]
160K 2022-07-24
- Time concepts in physics, biology, and pharmacokinetics
Harold Boxenbaum
J. Pharm. Sci. 75, 1053-1061 (1986)
[DOI: 10.1002/jps.2600751107] [PDF]
1.2M 2022-07-24
- Novel self-floating tablet for enhanced oral bioavailability of metformin based on cellulose
Hyun Wook Huh, Young-Guk Na, HeeChol Kang, Minki Kim, Mingu Han, Thi Mai Anh Pham, Hyeonmin Lee, Jong-Suep Baek, Hong-Ki Lee, Cheong-Weon Cho
Int. J. Pharm. 592, 120113 (2021)
[DOI: 10.1016/j.ijpharm.2020.120113] [PDF]
2.2M 2022-07-23
- Reduced bioavailability and effect of furosemide given with food
B. Beermann & C. Midskov
Eur. J. Clin. Pharmacol. 29, 725-727 (1986)
[DOI: 10.1007/BF00615967] [PDF]
236K 2022-07-23
- Pharmacokinetics of Furosemide in Man After Intravenous and Oral Administration. Application of Moment Analysis
M. M. Hammarlund, L. K. Paalzow, and B. Odlind
Eur. J. Clin. Pharmacol. 26, 197-207 (1984)
[DOI: 10.1007/BF00630286] [PDF]
1012K 2022-07-23
- BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide
Milica Markovic, Moran Zur, Inna Ragatsky, Sandra Cvijic and Arik Dahan
Pharmaceutics 12, 1175 (2020)
[DOI: 10.3390/pharmaceutics12121175] [PDF]
2.5M 2022-07-23
1.8M 2022-07-20
- Bioavailability of digoxin
E. J. Fraser, R. H. Leach, J. W. Poston
Lancet 300, 541-541 (1972)
[DOI: 10.1016/S0140-6736(72)91936-8] [PDF]
136K 2022-07-10
- Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs
Fang Wu, Heta Shah, Min Li, Peng Duan, Ping Zhao, Sandra Suarez, Kimberly Raines, Yang Zhao, Meng Wang, Ho-pi Lin, John Duan, Lawrence Yu, Paul Seo
AAPS J. 23, 31 (2021)
[DOI: 10.1208/s12248-021-00564-2] [PDF]
1.1M 2022-07-06
- Comparative bioavailability of three brands of ampicillin
C. MacLeod, H. Rabin, J. Ruedy, M. Caron, D. Zarowny, and R. O. Davies
Can. Med. Ass. J. 107, 203-209 (1972)
[DOI: www.cmaj.ca/content/107/3/203] [PDF]
1.2M 2022-06-07
- Brand, Generic Drugs Differ In Man; Absorption Rates Vary
C. M. Martin, M. Rubin, W. E. O'Malley, V. F. Garagusi, C. E. McCauley
JAMA 205, (9) 23-24, 30 (1968)
[DOI: 10.1001/jama.1968.03140350005003] [PDF]
2.8M 2022-06-07
- A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes
Meir Bialer
J. Pharmacokin. Biopharm. 8, 111-113 (1980)
[DOI: 10.1007/BF01059453] [PDF]
140K 2022-06-05
- Concentration Ratio Method to Determinethe Rate Constant for the Special Case when ka = ke
Indravadan H. Patel
J. Pharm. Sci. 73, 8591-861 (1984)
[DOI: 10.1002/jps.2600730648] [PDF]
288K 2022-06-05
- History of pharmacokinetics
John G. Wagner
Pharmacol. Ther. 12, 537-562 (1981)
[DOI: 10.1016/0163-7258(81)90097-8] [PDF]
2.2M 2022-06-05
- Harry Bateman 1882-1946
F. D. Murnaghan
Bull. Am. Math. Soc. 54, 88-103 (1948)
[DOI: https://doi.org/10.1090/S0002-9904-1948-08955-8] [PDF]
1.8M 2022-06-05
- Editor's note on the themed issue: integration of machine learning and quantitative systems pharmacology
Peter L. Bonate
J. Pharmacokin. Pharmacodyn. 49, 1-3 (2022)
[DOI: 10.1007/s10928-022-09803-1] [PDF]
136K 2022-06-05
- Modeling Drug Dissolution in 3-Dimensional Space
Chi So, Po-Chang Chiang & Chen Mao
Pharm. Res. 39, 907-917 (2022)
[DOI: 10.1007/s11095-022-03270-6] [PDF]
1.7M 2022-06-01
- A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold-labeled venetoclax, from chemistry to the clinic
Amr Alaarg, Rajeev Menon, David Rizzo, Yemin Liu, Jeffrey Bien, Tricia Elkinton, Timothy Grieme, Lutz R. Asmus, Ahmed Hamed Salem
Clin. Transl. Sci. 15, 244-254 (2022)
[DOI: 10.1111/cts.13144] [PDF]
444K 2022-05-26
- Investigation of bioequivalence
EMA
(2010)
[Source] [PDF]
236K 2022-05-17
- Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
Chi-Yuan Wu & Leslie Z. Benet
Pharm. Res. 22, 11-23 (2005)
[DOI: 10.1007/s11095-004-9004-4] [PDF]
388K 2022-05-16
- Bioequivalence: tried and tested
Robert Schall, Laszlo Endrenyi
Cardiovasc. J. Afr. 21, 69-71 (2010)
[Source] [PDF]
728K 2022-05-08
- Evaluation of Truncated Areas in the Assessment of Bioequivalence of Immediate Release Formulations of Drugs with Long Half-Lives and of Cmax with Different Dissolution Rates
Pradeep Sathe, Jurgen Venitz, Lawrence Lesko
Pharm. Res. 16, 939-943 (1999)
[DOI: 10.1023/A:1018898624643] [PDF]
892K 2022-05-05
- Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen
Ioannis Loisios-Konstantinidis, Rodrigo Cristofoletti, Nikoletta Fotaki, David B.Turner, Jennifer Dressman
Eur. J. Pharmaceut. Sci. 143, 205170 (2020)
[DOI: 10.1016/j.ejps.2019.105170] [PDF]
3.4M 2022-04-27
- Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions
Alison Margolskee, Adam S. Darwich, Aleksandra Galetin, Amin Rostami-Hodjegan & Leon Aarons
AAPS J. 18, 321-332 (2016)
[DOI: 10.1208/s12248-015-9849-y] [PDF]
2.5M 2022-04-10
- New method for calculating the intrinsic absorption rate of drugs
J. C. Loo, S. Riegelman
J. Pharm. Sci. 57, 918-928 (1968)
[DOI: 10.1002/jps.2600570602] [PDF]
1012K 2022-04-10
- Per cent absorbed time plots derived from blood level and/or urinary excretion data
J. G. Wagner, E. Nelson
J. Pharm. Sci. 52, 610-611 (1963)
[DOI: 10.1002/jps.2600520629] [PDF]
184K 2022-04-10
- State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
Giovanni Bocci, Tudor I. Oprea, Leslie Z. Benet
AAPS J. 24, 37 (2022)
[DOI: 10.1208/s12248-022-00687-0] [PDF]
1.1M 2022-04-09
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy P. Painter, Wayne Holman, Jim A. Bush, Firas Almazedi, Hamzah Malik, Nicola C. J. E. Eraut, Merribeth J. Morin, Laura J. Szewczyk, George R. Painter
Antimicrobial Agents and Chemotherapy 65 e02428-20 (2021)
[DOI: 10.1128/AAC.02428-20] [PDF]
944K 2022-03-28
- Population pharmacokinetic analysis of axitinib in healthy volunteers
May Garrett, Bill Poland, Meghan Brennan, Brian Hee, Yazdi K. Pithavala & Michael A. Amantea
Br. J. Clin. Pharmacol. 77, 480-492 (2013)
[DOI: 10.1111/bcp.12206] [PDF]
1.8M 2022-03-28
- Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial
Li Sun, Hankun Li, Kenneth Willson, Sheila Breidinger, Matthew L. Rizk, Larissa Wenning, Eric J. Woolf
Anal. Chem. 84, 8614-8621 (2012)
[DOI: 10.1021/ac301581h] [PDF]
588K 2022-01-26
- Clinical pharmacokinetics of pioglitazone
D. A. Eckland, M. Danhof
Exp. Clin. Endocrinol. Diabetes 108, S234-242 (2000)
[DOI: 10.1055/s-2000-8525] [PDF]
120K 2022-01-26
- Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm
Filippos Kesisoglou and Amitava Mitra
AAPS J. 17, 1224-1236 (2015)
[DOI: 10.1208/s12248-015-9781-1] [PDF]
1.3M 2022-01-26
- Clinical pharmacokinetics of dipyridamole
Thorir D. Bjornsson, Cheryl Mahony
Thrombosis Research 29, 93-104 (1983)
[DOI: 10.1016/0049-3848(83)90364-X] [PDF]
940K 2022-01-26
- A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations
Martin Bergstrand, Erik Soderlind, Ulf G. Eriksson, Werner Weitschies & Mats O. Karlsson
Pharm. Res. 29, 574-584 (2012)
[DOI: 10.1007/s11095-011-0595-2] [PDF]
852K 2022-01-26
- A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations
Martin Bergstrand, Erik Soderlind, Ulf G. Eriksson, Werner Weitschies, Mats O. Karlsson
Pharm. Res. 29, 695-706 (2012)
[DOI: 10.1007/s11095-011-0594-3] [PDF]
1.1M 2022-01-26
- Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics
M. Bergstrand, E. Soderlind, W. Weitschies, M. O. Karlsson
Clin. Pharmacol. Therap. 86, 77-83 (2009)
[DOI: 10.1038/clpt.2009.43] [PDF]
148K 2022-01-26
- Integration of precipitation kinetics from an in vitro, multicompartment transfer system and mechanistic oral absorption modeling pharmacokinetic prediction of weakly basic drugs
Sanjaykumar Patel, WeiZhu, Binfeng Xia, Navneet Sharma, Andre Hermans, Jason D. Ehrick, Filippos Kesisoglou, Justin Pennington
J. Pharm. Sci. 108, 574-583 (2019)
[DOI: 10.1016/j.xphs.2018.10.051] [PDF]
1.6M 2022-01-26
- Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption
Filippos Kesisoglou, Anand Balakrishnan, Kimberly Manser
J. Pharm. Sci. 105, 722-728 (2016)
[DOI: 10.1002/jps.24674] [PDF]
568K 2022-01-26
- Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions
Marina Statelova, Rene Holm, Nikoletta Fotaki, Christos Reppas, Maria Vertzoni
AAPS J. 22, 126 (2020)
[DOI: 10.1208/s12248-020-00504-6] [PDF]
2.2M 2022-01-18
- Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension
Marina Statelova, Rene Holm, Nikoletta Fotaki, Christos Reppas, Maria Vertzoni
AAPS J. 22, 146 (2020)
[DOI: 10.1208/s12248-020-00522-4] [PDF]
2.6M 2022-01-18
- On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food
Marina Statelova, Konstantinos Goumas, Nikoletta Fotaki, Rene Holm, Mira Symillides, Christos Reppas, Maria Vertzoni
AAPS J. 22, 6 (2020)
[DOI: 10.1208/s12248-019-0380-4] [PDF]
732K 2022-01-18
- An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects
A. J. Glazko, A. W. Kinkel, W. C. Alegnani, E. L. Holmes
Clin. Pharmacol. Therap. 9, 472-483 (1968)
[DOI: 10.1002/cpt196894472] [PDF]
1.4M 2021-12-19
- Outbreak of Anticonvulsant Intoxication in an Australian City
J. H. Tyrer, M. J. Eadie, J. M. Sutherland, W. D. Hooper
Br. Med. J. 4, 271-273 (1970)
[DOI: 10.1136/bmj.4.5730.271] [PDF]
716K 2021-12-19
- Blood Quinidine Concentrations as a Guide in the Treatment of Cardiac Arrhythmias
Maurice Sokolow, and A. L. Edgar
Circulation 1, 576-592 (1950)
[DOI: 10.1161/01.CIR.1.4.576] [PDF]
2.5M 2021-12-19
408K 2021-12-17
- Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation
Edgar A. Mueller, John M. Kovarik, Johannes B. van Bree, Joachim Grevel, Peter W. Lucker & Klaus Kutz
Pharm. Res. 11 151-155 (1994)
[DOI: 10.1023/a:1018922517162] [PDF]
908K 2021-12-14
- Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave
Jessica T. Davis, Matteo Chinazzi, Nicola Perra, Kunpeng Mu, Ana Pastore y Piontti, Marco Ajelli, Natalie E. Dean, Corrado Gioannini, Maria Litvinova, Stefano Merler, Luca Rossi, Kaiyuan Sun, Xinyue Xiong, Ira M. Longini, M. Elizabeth Halloran, Cecile Viboud, Alessandro Vespignani
Nature 600, 127-132 (2021)
[DOI: 10.1038/s41586-021-04130-w] [PDF]
3.5M 2021-12-02
- On Bayesian Analysis and Hypothesis Testing in the Determination of Bioequivalence
Donald J. Schuirmann, Stella Grosser, Somesh Chattopadhyay and Shein-Chung Chow
Clin. Pharmacol. Therap. 105, 304-306 (2019)
[DOI: 10.1002/cpt.1291] [PDF]
76K 2021-11-30
- Bayesian Approach to Establish Bioequivalence: Why and How?
Carl C. Peck and Gregory Campbell
Clin. Pharmacol. Therap. 105, 301-303 (2019)
[DOI: 10.1002/cpt.1288] [PDF]
84K 2021-11-30
- A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach
H. Markus Weiss, Ken-Ichi Umehara, Veit J. Erpenbeck, Meredith Cain, Janardhana Vemula, Walid Elbast, and Markus Zollinger
Drug Metabolism and Disposition 48, 917-924 (2020)
[DOI: 10.1124/dmd.120.090852] [PDF]
1.4M 2021-11-25
- Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
Yvonne Y. Lau, Wen Gu, Tiffany Lin, Dongweon Song, Richard Yu, and Jeffrey W. Scott
J. Clin. Pharmacol. 56, 559-566 (2016)
[DOI: 10.1002/jcph.619] [PDF]
372K 2021-11-25
- Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
Yan Ji, Ahmed M. Abdelhady, Tanay S. Samant, Shu Yang, and Karen Rodriguez Lorenc
Clinical Pharmacology in Drug Development 9, 855-866 (2020)
[DOI: 10.1002/cpdd.853] [PDF]
788K 2021-11-25
- 3-(3-Alkylamino-2-hydroxypropoxy)-derivatives of estratriene. Synthesis and preliminary pharmacological study
M. Kazanis, P. Macheras, A. Vavayannis
Chem. Chron. New Ser. 18, 41-46 (1989)
[PDF]
108K 2021-11-19
1.2M 2021-11-11
4.5M 2021-11-11
- Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies
Tycho Heimbach, Filippos Kesisoglou, Jasmina Novakovic, Christophe Tistaert, Martin Mueller-Zsigmondy, Sivacharan Kollipara, Tausif Ahmed, Amitava Mitra, Sandra Suarez-Sharp
J. Pharm. Sci. 110 3896-2906 (2021)
[DOI: 10.1016/j.xphs.2021.09.017] [PDF]
1.8M 2021-10-30
- Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Jeroen Roosendaal, Stefanie L. Groenland, Hilde Rosing, Luc Lucas, Nikkie Venekamp, Bastiaan Nuijen, Alwin D. R. Huitema, Jos H. Beijnen, Neeltje Steeghs
Eur. J. Clin. Pharmacol. 76, 1075-1082 (2020)
[DOI: 10.1007/s00228-020-02888-y] [PDF]
484K 2021-10-26
- Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate
Gary J Muirhead, David J Rance, Donald K Walker, and Philip Wastall
Br. J. Clin. Pharmacol. 53, 13S-20S (2002)
[DOI: 10.1046/j.0306-5251.2001.00028.x] [PDF]
120K 2021-10-25
- A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men
Jung-woo Chae, Jeong-won Seo, Bimit Mahat, Hwi-yeol Yun, In-hwan Baek, Byung-yo Lee, Dong-hyun Kim & Kwang-il Kwon
Drug Developm. Ind. Pharmacy 40, 1325-1329 (2013)
[DOI: 10.3109/03639045.2013.819880] [PDF]
260K 2021-10-25
- Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
G. Flesch, Ph. Müller, P. Lloyd
Eur. J. Clin. Pharmacol. 52, 115-120 (1997)
[DOI: 10.1007/s002280050259] [PDF]
172K 2021-10-25
- Absolute Bioavailability, Pharmacokinetics, and Urinary Excretion of the Novel Antimigraine Agent Almotriptan in Healthy Male Volunteers
Josep M. Jansat, Joan Costa, Pau Salva, Francisco J. Fernandez, and Antonio Martinez-Tobed
J. Pharmacokin. Pharmacodyn. 42, 1303-1310 (2002)
[DOI: 10.1177/0091270002239359] [PDF]
92K 2021-10-25
- Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers
Timothy M Rawson, Sally A N Gowers, David M E Freeman, Richard C Wilson, Sanjiv Sharma, Mark Gilchrist, Alasdair MacGowan, Andrew Lovering, Mark Bayliss, Mathew Kyriakides, Pantelis Georgiou, Anthony E G Cass, Danny O'Hare, Alison H Holmes
The Lancet Digital Health 1, e335-e343 (2019)
[DOI: 10.1016/S2589-7500(19)30131-1] [PDF]
1.5M 2021-10-16
- Burden and characteristics of COVID-19 in the United States during 2020
Pei Sen, Teresa K. Yamana, Sasikiran Kandula, Marta Galanti & Jeffrey Shaman
Nature 598, 338-341 (2021)
[DOI: 10.1038/s41586-021-03914-4] [PDF]
5.2M 2021-10-16
Correction to: Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations
Pavlos Chryssafidis, Athanasios A. Tsekouras, Panos Macheras
Pharm. Res. 38, 1633 (2021)
[DOI: 10.1007/s11095-021-03101-0] [PDF]
100K 2021-10-09
- Glc analysis following oxidation of phenytoin - an inexpensive method for routine determination of the drug in plasma
P Macheras, A Rosen
Pharmazie 39, 322-325 (1984)
[DOI: 10.24355/dbbs.084-201811191154-0][PDF]
7.6M 2021-10-09
- Construction of a diflunisal ion sensor and its use in automated flow-injection methods for assay, content uniformity, and dissolution studies of formulations
P Solich, PE Macheras, MA Koupparis
J. Pharm. Sci. 84, 889-894 (1995)
[DOI: 10.1002/jps.2600840720] [PDF]
752K 2021-10-09
- The Geometric Mean Functional Relationship Approach to Linear Regression in Pharmaceutical Studies: Application to the Estimation of Binding Parameters
Georgia Valsami and Panos Macheras
Pharm. Sci. 1, 551-554 (1995)
[DOI: 10.1111/j.2042-7158.1995.tb00377.x] [PDF]
272K 2021-10-07
- An automated flow-injection serial dynamic dialysis technique for drug-protein binding-studies
PE Macheras, MA Koupparis
Anal. Chim. Acta 185, 65-73 (1986)
[DOI: 10.1016/0003-2670(86)80033-2] [PDF]
588K 2021-10-05
- The effect of protein on the dissolution of phenytoin
A Rosen, P Macheras
J. Pharm. Pharmacol. 36, 723-727 (1984)
[DOI: 10.1111/j.2042-7158.1984.tb04859.x] [PDF]
380K 2021-10-05
- Effect of protein on the absorption of phenytoin through everted gut preparations
A Rosen, P Macheras
J. Pharm. Pharmacol. 37, 154-158 (1985)
[DOI: 10.1111/j.2042-7158.1985.tb05031.x] [PDF]
380K 2021-10-05
- Developments in the concentration ratio method
PE Macheras
J. Pharm. Sci. 74, 1021-1021 (1985)
[DOI: 10.1002/jps.2600740927] [PDF]
76K 2021-10-05
- Graphical approach for determining whether absorption and elimination rate constants are equal in the one-compartment open model with 1st-order processes
PE Macheras
J. Pharm. Sci. 74, 582-584 (1985)
[DOI: 10.1002/jps.2600740521] [PDF]
336K 2021-10-05
- Studies on drug milk freeze-dried formulations I. Bioavailability of sulfamethizole and dicumarol formulations
PE Macheras, CI Reppas
J. Pharm. Sci. 75, 692-696 (1986)
[DOI: 10.1002/jps.2600750716] [PDF]
580K 2021-10-05
- Studies on freeze-dried drug-milk formulations II. Effect of regenerated fluid volume on nitrofurantoin bioavailability
PE Macheras, CI Reppas
J. Pharm. Sci. 75, 1145-1150 (1986)
[DOI: 10.1002/jps.2600751206] [PDF]
564K 2021-10-05
- Improvement without computer-assistance of the graphically estimated parameters of the linear one-compartment open model
PE Macheras
Biopharm. Drug Dispos. 8, 387-394 (1987)
[DOI: 10.1002/bdd.2510080409] [PDF]
260K 2021-10-05
- Effect of temperature and fat-content on the binding of hydrochlorothiazide and chlorothiazide to milk
PE Macheras, MA Koupparis, SG Antimisiaris
J. Pharm. Sci. 77, 334-336 (1988)
[DOI: 10.1002/jps.2600770411] [PDF]
380K 2021-10-05
- Pharmacokinetics of acetaminophen after intramuscular administration
P Macheras, M Parissi-Poulos, L Poulos
Biopharm. Drug Dispos. 10, 101-105 (1989)
[DOI: 10.1002/bdd.2510100111] [PDF]
204K 2021-10-05
- Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept
PE Macheras, MY Symillides
Biopharm. Drug Dispos. 10, 43-53 (1989)
[DOI: 10.1002/bdd.2510100106] [PDF]
508K 2021-10-05
- Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis
GN Valsami, PE Macheras, MA Koupparis
Analyst 114, 387-391 (1989)
[DOI: 10.1039/an9891400387] [PDF]
596K 2021-10-05
- Effect of temperature and fat-content on the solubility of hydrochlorothiazide and chlorothiazide in milk
PE Macheras, MA Koupparis, SG Antimisiaris
J. Pharm. Sci. 78, 933-936 (1989)
[DOI: 10.1002/jps.2600781111] [PDF]
492K 2021-10-05
- Evaluation of controlled release formulations - estimation of the duration of the zero-order absorption and ascertainment of absorption kinetics
P Macheras
Biopharm. Drug Dispos. 12, 173-187 (1991)
[DOI: 10.1002/bdd.2510120302] [PDF]
548K 2021-10-05
- Unusual solubility behavior of cyclosporine-a in aqueous-media
G Ismailos, C Reppas, JB Dressman, P Macheras
J. Pharm. Pharmacol. 43, 287-289 (1991)
[DOI: 10.1111/j.2042-7158.1991.tb06688.x] [PDF]
300K 2021-10-05
- Bioavailability study of a freeze-dried sodium phenytoin-milk formulation
P Macheras, G Ismailos, C Reppas
Biopharm. Drug Dispos. 12, 687-695 (1991)
[DOI: 10.1002/bdd.2510120906] [PDF]
444K 2021-10-05
- Binding study of the fluorescence probe 1-anilino-8-naphthalenesulfonate to human plasma and human and bovine serum-albumin using potentiometric titration
GN Valsami, PE Macheras, MA Koupparis
Pharm. Res. 8, 888-892 (1991)
[DOI: 10.1023/A:1015855613083] [PDF]
916K 2021-10-05
- Equations for the fraction of bioavailable dose remaining in the body in the one-compartment model
P Macheras, M Symillides, C Reppas
Biopharm. Drug Dispos. 13, 229-232 (1992)
[DOI: 10.1002/bdd.2510130309] [PDF]
148K 2021-10-05
- Use of 1-anilino-8-napthalenesulphonate as an ion probe for the potentiometric study of the binding of sulfonamides to bovine serum-albumin and plasma
A Angelakou, G Valsami, M Koupparis, P Macheras
J. Pharm. Pharmacol. 45, 434-438 (1993)
[DOI: 10.1111/j.2042-7158.1993.tb05571.x] [PDF]
480K 2021-10-05
- Automated flow-injection serial dynamic dialysis technique in the study of drug-binding with cyclodextrins
EE Sideris, CA Georgiou, MA Koupparis, PE Macheras
Anal. Chim. Acta 289, 87-95 (1994)
[DOI: 10.1016/0003-2670(94)80011-1] [PDF]
792K 2021-10-05
- Automated flow-injection technique for use in dissolution studies of sustained-release formulations - Application to iron(II) formulations
CA Georgiou, GN Valsami, PE Macheras, MA Koupparis
J. Pharm. Biomed. Anal. 12, 635-641 (1994)
[DOI: 10.1016/0731-7085(93)E0015-F] [PDF]
580K 2021-10-05
- General treatment of competitive-binding as applied to the potentiometric ion probe technique - Application to the interaction of nonsteroidal antiinflammatory drugs with bovine serum-albumin
AT Angelakou, EE Sideris, GN Valsami, MA Koupparis, PE Macheras
J. Pharm. Sci. 83, 1150-1154 (1994)
[DOI: 10.1002/jps.2600830816] [PDF]
612K 2021-10-05
- The effect of polyethylene glycol on the charcoal adsorption of chlorpromazine studied by ion selective electrode potentiometry
J Atta-Politou, PE Macheras, MA Koupparis
J. Toxicol.-Clin. Toxicol. 34, 307-316 (1996)
[DOI: 10.3109/15563659609013795] [PDF]
984K 2021-10-05
- Nonlinear dynamics in Clinical Pharmacology: the paradigm of cortisol secretion and suppression
A Dokoumetzidis, A Iliadis, P Macheras
Br. J. Clin. Pharmacol. 54, 21-29 (2002)
[DOI: 10.1046/j.1365-2125.2002.01600.x] [PDF]
204K 2021-10-05
- Binding-studies of ions with cyclodextrins using ion-selective electrodes
GN Valsami, PE Macheras, MA Koupparis
J. Pharm. Sci. 79, 1087-1094 (1990)
[DOI: 10.1002/jps.2600791210] [PDF]
908K 2021-10-04
- Fraction of the bioavailable dose remaining in the body at the time of peak plasma-concentration in a linear, open, one-compartment model
P Macheras, C Reppas, M Symillides
J. Pharm. Sci. 81, 110-112 (1992)
[DOI: 10.1002/jps.2600810124] [PDF]
272K 2021-10-03
- On the assessment of the relative magnitude of rate constants in the linear open one-compartment model
P Macheras, M Symillides, C Reppas
J. Pharm. Sci. 81, 1231-1233 (1992)
[DOI: 10.1002/jps.2600811223] [PDF]
252K 2021-10-03
- Estimation of absorption rate-constant in a one-compartment model with the profile of the bioavailable dose eliminated as a function of multiples of half-life
P Macheras, M Symillides, C Reppas
J. Pharm. Sci. 82, 1298-1300 (1993)
[DOI: 10.1002/jps.2600821226] [PDF]
316K 2021-10-03
- Quantitative determination of cefepime in plasma and vitreous fluid by high-performance liquid chromatography
IN Valassis, M Parissi-Poulou, P Macheras
J. Chromatogr. B 721, 249-255 (1999)
[DOI: 10.1016/S0378-4347(98)00468-X] [PDF]
128K 2021-10-03
- Non-linear regression analysis with errors in both variables: Estimation of co-operative binding parameters
G Valsami, A Iliadis, P Macheras
Biopharm. Drug Dispos. 21, 7-14 (2000)
[DOI: 10.1002/1099-081X(200001)21:1<7::AID-BDD210>3.0.CO;2-F] [PDF]
236K 2021-10-03
- Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients
FX Caroli-Bose, A Iliadis, L Salmon, P Macheras, AM Montet, A Bourgeon, R Garraffo, JP Delmont, JC Montet
Fundam. Clin. Pharmacol. 14, 601-609 (2000)
[DOI: 10.1111/j.1472-8206.2000.tb00446.x] [PDF]
672K 2021-10-03
- Cyclosporin a pharmacokinetics in liver transplant recipients effect of ursodeoxycholic acid.
A Iliadis, P Macheras, FX Caroli-Bosc, AM Montet, L Salmon, JC Montet
Gastroenterology 118, A984-A984 (2000)
[DOI: 10.1016/S0016-5085(00)86082-5] [PDF]
168K 2021-10-03
- A model for transport and dispersion in the circulatory system based on the vascular fractal tree
A Dokoumetzidis, P Macheras
Ann. Biomed. Eng. 31, 284-293 (2003)
[DOI: 10.1114/1.1555627] [PDF]
276K 2021-10-03
- The heterogenous course of drug transit through the body
A Dokoumetzidis, V Karalis, A Iliadis, P Macheras
Trends Pharmacol. Sci. 25, 140-146 (2004)
[DOI: 10.1016/j.tips.2004.01.008] [PDF]
672K 2021-10-03
- Michaelis-Menten kinetics under spatially constrained conditions: Application to mibefradil pharmacokinetics
K Kosmidis, V Karalis, P Argyrakis, P Macheras
Biophys. J. 87, 1498-1506 (2004)
[DOI: 10.1529/biophysj.104.042143] [PDF]
172K 2021-10-03
- Modeling and Monte Carlo simulations in oral drug absorption
A Dokoumetzidis, K Kosmidis, P Argyrakis, P Macheras
Basic Clin. Pharmacol. Toxicol. 96, 200-205 (2005)
[DOI: 10.1111/j.1742-7843.2005.pto960309.x] [PDF]
176K 2021-10-03
- Bicompartmental kinetics of tobramycin analysed with a wide range of covariates
G Inclan, E Suarez, R Calvo, C Aguirre, P Macheras, M Gazouli, JC Lukas
Int. J. Antimicrob. Agents 26, 304-311 (2005)
[DOI: 10.1016/j.ijantimicag.2005.05.004] [PDF]
188K 2021-10-03
- In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique
A. Davilas, M. Koupparis, P. Macheras, G. Valsami
J. Pharm. Pharmacol. 58, 1467-1474 (2006)
[DOI: 10.1211/jpp.58.11.0007] [PDF]
444K 2021-10-03
- A comment on "adverse drug reactions and avalanches: Life at the edge of chaos"
Aristides Dokoumetzidis, Panos Macheras
J. Clin. Pharmacol. 46, 1057-1058 (2006)
[DOI: 10.1177/0091270006291620] [PDF]
140K 2021-10-03
- Modelling and simulation in drug absorption processes
A. Dokoumetzidis, G. Valsami, P. Macheras
Xenobiotica 37, 1052-1065 (2007)
[DOI: 10.1080/00498250701502114] [PDF]
408K 2021-10-03
- IVIVC of controlled release formulations: Physiological-dynamical reasons for their failure
A. Dokoumetzidis, P. Macheras
J. Control. Release 129, 76-78 (2008)
[DOI: 10.1016/j.jconrel.2008.04.005] [PDF]
236K 2021-10-03
- Effect of Cyclodextrin Complexation on the Aqueous Solubility and Solubility/Dose Ratio of Praziquantel
Stratos Maragos, Helen Archontaki, Panos Macheras, Georgia Valsami
AAPS PharmSciTech 10, 1444-1451 (2009)
[DOI: 10.1208/s12249-009-9346-7] [PDF]
228K 2021-10-03
- Examining the Role of Metabolites in Bioequivalence Assessment
Vangelis Karalis, Panos Macheras
J. Pharm. Pharmaceut. Sci. 13, 198-217 (2010)
[DOI: 10.18433/J35889] [PDF]
1.8M 2021-10-03
- Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations
Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
Basic Clin. Pharmacol. Toxicol. 106, 168-172 (2010)
[DOI: 10.1111/j.1742-7843.2009.00506.x] [PDF]
112K 2021-10-03
- Computational-Regulatory Developments in the Prediction of Oral Drug Absorption
G. Valsami, P. Macheras
Mol. Inf. 30, 112-121 (2011)
[DOI: 10.1002/minf.201000171] [PDF]
448K 2021-10-03
- Novel methods to assess bioequivalence
Vangelis Karalis, Mira Symillides, Panos Macheras
Expert Opin. Drug Metab. Toxicol. 7, 79-88 (2011)
[DOI: 10.1517/17425255.2011.539202] [PDF]
368K 2021-10-03
- Supersaturated dissolution data and their interpretation: the TPGS-carbamazepine model case
Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
J. Pharm. Pharmacol. 63, 352-361 (2011)
[DOI: 10.1111/j.2042-7158.2010.01226.x] [PDF]
428K 2021-10-03
- Current regulatory approaches of bioequivalence testing
Vangelis Karalis, Panos Macheras
Expert Opin. Drug Metab. Toxicol. 8, 929-942 (2012)
[DOI: 10.1517/17425255.2012.690394] [PDF]
440K 2021-10-03
- Exploring the Relationships Between Scaled Bioequivalence Limits and Within-Subject Variability
Mira Symillides, Vangelis Karalis, Panos Macheras
J. Pharm. Sci. 102, 297-301 (2013)
[DOI: 10.1002/jps.23365] [PDF]
144K 2021-10-03
- Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review
Panos Macheras, Vangelis Karalis, Georgia Valsami
J. Pharm. Sci. 102, 3018-3036 (2013)
[DOI: 10.1002/jps.23534] [PDF]
828K 2021-10-03
- On the statistical model of the two-stage designs in bioequivalence assessment
Vangelis Karalis, Panos Macheras
J. Pharm. Pharmacol. 66, 48-52 (2014)
[DOI: 10.1111/jphp.12164] [PDF]
672K 2021-10-03
- Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations
Vangelis Karalis, Panos Macheras, Meir Bialer
CNS Drugs 28, 69-77 (2014)
[DOI: 10.1007/s40263-013-0112-8] [PDF]
400K 2021-10-03
- Comment and reply on: A randomized crossover trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma of chronic obstructive pulmonary disease
Panos Macheras
Expert Opin. Drug Deliv. 11, 823-824 (2014)
[DOI: 10.1517/17425247.2014.889648] [PDF]
384K 2021-10-03
- Modeling and administration scheduling of fractional-order pharmacokinetic systems
Domagoj Herceg, Sotiris Ntouskas, Pantelis Sopasakis, Aris Dokoumetzidis, Panos Macheras, Haralambos Sarimveis, Panagiotis Patrinos
IFAC PAPERSONLINE 50, 9742-9747 (2017)
[DOI: 10.1016/j.ifacol.2017.08.2178] [PDF]
644K 2021-10-03
- A commentary on fractionalization of multi-compartmental models
Aristides Dokoumetzidis, Richard Magin, Panos Macheras
J. Pharmacokinet. Pharmacodyn. 37, 203-207 (2010)
[DOI: 10.1007/s10928-010-9153-5] [PDF]
224K 2021-10-03
- Fractional calculus in pharmacokinetics
Pantelis Sopasakis, Haralambos Sarimveis, Panos Macheras, Aristides Dokoumetzidis
J. Pharmacokinet. Pharmacodyn. 45, 107-125 (2018)
[DOI: 10.1007/s10928-017-9547-8] [PDF]
852K 2021-10-03
- On the unphysical hypotheses in pharmacokinetics and oral drug absorption: Time to utilize instantaneous rate coefficients instead of rate constants
Panteleimon D. Mavroudis, Kosmas Kosmidis, Panos Macheras
Eur. J. Pharm. Sci. 130, 137-146 (2019)
[DOI: 10.1016/j.ejps.2019.01.027] [PDF]
3.1M 2021-10-03
- A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs
Panos Macheras, Athanassios Iliadis, Georgia Melagraki
Eur. J. Pharm. Sci. 117, 98-106 (2018)
[DOI: 10.1016/j.ejps.2018.02.003] [PDF]
844K 2021-10-03
- Biopharmaceutic classification of drugs revisited
Chrysa Daousani, Panos Macheras
Eur. J. Pharm. Sci. 95, 82-87 (2016)
[DOI: 10.1016/j.ejps.2016.08.001] [PDF]
440K 2021-10-03
- Quantitative assessment of the switchability of generic products
Vangelis Karalis, Meir Bialer, Panos Macheras
Eur. J. Pharm. Sci. 50, 476-483 (2013)
[DOI: 10.1016/j.ejps.2013.08.023] [PDF]
2.0M 2021-10-03
- On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline
Vangelis Karalis, Mira Symillides, Panos Macheras
Eur. J. Pharm. Sci. 44, 497-505 (2011)
[DOI: 10.1016/j.ejps.2011.09.008] [PDF]
1.2M 2021-10-03
- Power law IVIVC: An application of fractional kinetics for drug release and absorption
John Kytariolos, Aristides Dokoumetzidis, Panos Macheras
Eur. J. Pharm. Sci. 41, 299-304 (2010)
[DOI: 10.1016/j.ejps.2010.06.015] [PDF]
360K 2021-10-03
- Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: Focus on human exposure to drugs
Vangelis Karalis, Mira Symillides, Panos Macheras
Eur. J. Pharm. Sci. 38, 55-63 (2009)
[DOI: 10.1016/j.ejps.2009.05.013] [PDF]
1.3M 2021-10-03
- Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties
V Karalis, P Macheras, M Symillides
Eur. J. Pharm. Sci. 26, 54-61 (2005)
[DOI: 10.1016/j.ejps.2005.04.019] [PDF]
316K 2021-10-03
- Quantitative structure-pharmacokinetic relationships for disposition parameters of cephalosporins
V Karalis, A Tsantili-Kakoulidou, P Macheras
Eur. J. Pharm. Sci. 20, 115-123 (2003)
[DOI: 10.1016/S0928-0987(03)00177-5] [PDF]
592K 2021-10-03
- Pharmacodynamic considerations in bioequivalence assessment: comparison of novel and existing metrics
V Karalis, P Macheras
Eur. J. Pharm. Sci. 19, 45-56 (2003)
[DOI: 10.1016/S0928-0987(03)00064-2] [PDF]
1.9M 2021-10-03
- On the use of partial AUC as an early exposure metric
A Dokoumetzidis, P Macheras
Eur. J. Pharm. Sci. 10, 91-95 (2000)
[DOI: 10.1016/S0928-0987(99)00095-0] [PDF]
272K 2021-10-03
- Studies on the interaction of diflunisal ion with cyclodextrins using ion-selective electrode potentiometry
EE Sideris, GN Valsami, MA Koupparis, PE Macheras
Eur. J. Pharm. Sci. 7, 271-278 (1999)
[DOI: 10.1016/S0928-0987(98)00035-9] [PDF]
200K 2021-10-03
- A displacement approach for competitive drug-protein binding studies using the potentiometric 1-anilino-8-naphthalene-sulfonate probe technique
A Angelakou, G Valsami, P Macheras, M Koupparis
Eur. J. Pharm. Sci. 9, 123-130 (1999)
[DOI: 10.1016/S0928-0987(99)00036-6] [PDF]
108K 2021-10-03
- Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs
C Reppas, G Eleftheriou, P Macheras, M Symillides, JB Dressman
Eur. J. Pharm. Sci. 6, 131-139 (1998)
[DOI: 10.1016/S0928-0987(97)00077-8] [PDF]
132K 2021-10-03
- Development of a potentiometric kinetic method for drug adsorption studies: The chlorpromazine-charcoal model case
J Atta-Politou, M Koupparis, P Macheras
Eur. J. Pharm. Sci. 4, 223-230 (1996)
[DOI: 10.1016/0928-0987(95)00050-X] [PDF]
588K 2021-10-03
- Determination of fractal reaction dimension in dissolution studies
G Valsami, P Macheras
Eur. J. Pharm. Sci. 3, 163-169 (1995)
[DOI: 10.1016/0928-0987(95)00005-X] [PDF]
500K 2021-10-03
- Enhancement of cyclosporine-a solubility by d-alphatocopheryl-polyethylene-glycol-1000 succinate (tpgs)
G Ismailos, C Reppas, P Macheras
Eur. J. Pharm. Sci. 1, 269-271 (1994)
[DOI: 10.1016/0928-0987(94)90021-3] [PDF]
280K 2021-10-03
- In silico prediction of ADME and pharmacokinetics - Report of an expert meeting organised by COST B15
A Boobis, U Gundert-Remy, P Kremers, P Macheras, O Pelkonen
Eur. J. Pharm. Sci. 17, 183-193 (2002)
[DOI: 10.1016/S0928-0987(02)00185-9] [PDF]
112K 2021-10-03
- Some considerations concerning the effect of an increased rate of oral absorption on drug levels of protein-bound drugs
P Macheras, A Rosen
Int. J. Pharm. 6, 175-178 (1980)
[DOI: 10.1016/0378-5173(80)90090-3] [PDF]
268K 2021-10-03
- Quick method for the calculation of the absorption rate-constant of the linear one-compartment model using all available blood level data
P Macheras
Int. J. Pharm. 19, 339-343 (1984)
[DOI: 10.1016/0378-5173(84)90063-2] [PDF]
320K 2021-10-03
- Effect of absorption and elimination rates on the maintenance time of therapeutic drug levels - derivation of an equation for this time and its applications
P Macheras, A Rosen
Int. J. Pharm. 16, 353-359 (1983)
[DOI: 10.1016/0378-5173(83)90155-2] [PDF]
- Application of automated flow-injection analysis (fia) to dissolution studies
M Koupparis, P Macheras, C Reppas
Int. J. Pharm. 20, 325-333 (1984)
[DOI: 10.1016/0378-5173(84)90179-0] [PDF]
688K 2021-10-03
- Automated flow-injection colorimetric determination of acetaminophen for assays and dissolution studies of multicomponent dosage forms
M Koupparis, P Macheras, C Tsaprounis
Int. J. Pharm. 27, 349-359 (1985)
[DOI: 10.1016/0378-5173(85)90082-1] [PDF]
684K 2021-10-03
- An automated flow injection-serial dynamic dialysis technique for drug protein-binding studies
P Macheras, M Koupparis, C Tsaprounis
Int. J. Pharm. 30, 123-132 (1986)
[DOI: 10.1016/0378-5173(86)90072-4] [PDF]
796K 2021-10-03
- The use of constant volume ultrafiltration for dissolution studies
A Rosen, P Macheras, KD Howe
Int. J. Pharm. 32, 171-175 (1986)
[DOI: 10.1016/0378-5173(86)90176-6] [PDF]
444K 2021-10-03
- Drug dissolution studies in milk using the automated flow-injection serial dynamic dialysis technique
P Macheras, M Koupparis, C Tsaprounis
Int. J. Pharm. 33, 125-136 (1986)
[DOI: 10.1016/0378-5173(86)90046-3] [PDF]
980K 2021-10-03
- Determination of nitrofurantoin in urine by derivative spectroscopy
M Poulou, P Macheras
Int. J. Pharm. 34, 29-34 (1986)
[DOI: 10.1016/0378-5173(86)90006-2] [PDF]
492K 2021-10-03
- Dissolution of 4 controlled-release theophylline formulations in milk
P Macheras, M Koupparis, E Apostolelli
Int. J. Pharm. 36, 73-79 (1987)
[DOI: 10.1016/0378-5173(87)90239-0] [PDF]
508K 2021-10-03
- Dissolution and invitro permeation behaviors of dicumarol nitrofurantoin and sulfamethizole in the presence of protein
P Macheras, C Reppas
Int. J. Pharm. 37, 103-112 (1987)
[DOI: 10.1016/0378-5173(87)90014-7] [PDF]
848K 2021-10-03
- 2nd derivative UV spectrophotometric determination of hydrochlorothiazide and hydrochlorothiazide amiloride combination in tablets
M Parissi-Poulou, V Reizopoulou, M Koupparis, P Macheras
Int. J. Pharm. 51, 169-174 (1989)
[DOI: 10.1016/0378-5173(89)90251-2] [PDF]
336K 2021-10-03
- An invitro model for exploring CR theophylline milk-fat interactions
P Macheras, M Koupparis, S Antimisiaris
Int. J. Pharm. 54, 123-130 (1989)
[DOI: 10.1016/0378-5173(89)90331-1] [PDF]
548K 2021-10-03
- A new approach for the invivo evaluation of sustained-release dosage forms
P Macheras, M Symillides, M Georgiacodis
Int. J. Pharm. 52, 249-253 (1989)
[DOI: 10.1016/0378-5173(89)90227-5] [PDF]
564K 2021-10-03
- Modified hplc analysis of diltiazem in plasma for pharmacokinetic studies
M Parissi-Poulou, G Ismailos, P Macheras
Int. J. Pharm. 62, R13-R16 (1990)
[DOI: 10.1016/0378-5173(90)90244-X] [PDF]
304K 2021-10-03
- Modeling of supersaturated dissolution data
G Valsami, A Dokoumetzidis, P Macheras
Int. J. Pharm. 181, 153-157 (1999)
[DOI: 10.1016/S0378-5173(99)00020-4] [PDF]
96K 2021-10-03
- Analysis of Case II drug transport with radial and axial release from cylinders
K Kosmidis, E Rinaki, P Argyrakis, P Macheras
Int. J. Pharm. 254, 183-188 (2003)
[DOI: 10.1016/S0378-5173(03)00030-9] [PDF]
104K 2021-10-03
- Monte Carlo simulations for the study of drug release from matrices with high and low diffusivity areas
Kosmas Kosmidis, Panos Macheras
Int. J. Pharm. 343, 166-172 (2007)
[DOI: 10.1016/j.ijpharm.2007.05.021] [PDF]
844K 2021-10-03
- Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments
A. Dokoumetzidis, V. Papadopoulou, G. Valsami, P. Macheras
Int. J. Pharm. 355, 114-125 (2008)
[DOI: 10.1016/j.ijpharm.2007.11.056] [PDF]
444K 2021-10-03
- Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples
Vasiliki Papadopoulou, Georgia Valsami, Aristides Dokoumetzidis, Panos Macheras
Int. J. Pharm. 361, 70-77 (2008)
[DOI: 10.1016/j.ijpharm.2008.05.021] [PDF]
488K 2021-10-03
- Monte Carlo simulations of drug release from matrices with periodic layers of high and low diffusivity
Kosmas Kosmidis, Panos Macheras
Int. J. Pharm. 354, 111-116 (2008)
[DOI: 10.1016/j.ijpharm.2007.10.036] [PDF]
676K 2021-10-03
- Stability and physicochemical characterization of novel milk-based oral formulations
J. Kytariolos, G. Charkoftaki, J. R. Smith, G. Voyiatzis, A. Chrissanthopoulos, S. N. Yannopoulos, D. G. Fatouros, P. Macheras
Int. J. Pharm. 444, 128-138 (2013)
[DOI: 10.1016/j.ijpharm.2013.01.022] [PDF]
912K 2021-10-03
- On the ubiquitous presence of fractals and fractal concepts in pharmaceutical sciences: A review
Natassa Pippa, Aristides Dokoumetzidis, Costas Demetzos, Panos Macheras
Int. J. Pharm. 456, 340-352 (2013)
[DOI: 10.1016/j.ijpharm.2013.08.087] [PDF]
1.6M 2021-10-03
- Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence
Chrysa Daousani, Panos Macheras
Int. J. Pharm. 478, 606-609 (2015)
[DOI: 10.1016/j.ijpharm.2014.11.062] [PDF]
192K 2021-10-03
- Milk as a medium for pediatric formulations: Experimental findings and regulatory aspects
Konstantina Soulele, Panos Macheras
Int. J. Pharm. 492, 344-345 (2015)
[DOI: 10.1016/j.ijpharm.2015.05.015] [PDF]
204K 2021-10-03
- Monte Carlo simulations and fractional kinetics considerations for the Higuchi equation
Aristides Dokoumetzidis, Kosmas Kosmidis, Panos Macheras
Int. J. Pharm. 418, 100-103 (2011)
[DOI: 10.1016/j.ijpharm.2010.11.046] [PDF]
436K 2021-10-03
- Estimate of volume flow ratio of gastrointestinal (gi) fluids in humans using pharmacokinetic data
P Macheras, C Reppas, JB Dressman
Pharm. Res. 7, 518-522 (1990)
[DOI: 10.1023/A:1015825018361] [PDF]
768K 2021-10-02
- Drug-binding and solubility in milk
PE Macheras, MA Koupparis, SG Antimisiaris
Pharm. Res. 7, 537-541 (1990)
[DOI: 10.1023/A:1015881103340] [PDF]
840K 2021-10-02
- Binding of drugs in milk - the role of casein in milk protein-binding - comments on the paper by Stebler and Guentert
P Macheras, C Reppas, S Antimisiaris
Pharm. Res. 8, 550-550 (1991)
[DOI: 10.1023/A:1015832118593] [PDF]
88K 2021-10-02
- Complexation studies of cyclodextrins with tricyclic antidepressants using ion-selective electrodes
GN Valsami, MA Koupparis, PE Macheras
Pharm. Res. 9, 94-100 (1992)
[DOI: 10.1023/A:1018940013006] [PDF]
1.1M 2021-10-02
- Effect of cyclodextrins on protein-binding of drugs - The diflunisal hydroxypropyl-beta-cyclodextrin model case
EE Sideris, MA Koupparis, PE Macheras
Pharm. Res. 11, 90-95 (1994)
[DOI: 10.1023/A:1018901912619] [PDF]
1.1M 2021-10-02
- Evaluation of different metrics as indirect measures of rate of drug absorption from extended-release dosage forms at steady-state
C Reppas, LF Lacey, ON Keene, P Macheras, A Bye
Pharm. Res. 12, 103-107 (1995)
[DOI: 10.1023/A:1016246922519] [PDF]
776K 2021-10-02
- Carrier-mediated transport can obey fractal kinetics
P Macheras
Pharm. Res. 12, 541-548 (1995)
[DOI: 10.1023/A:1016201929304] [PDF]
1.3M 2021-10-02
- A population growth model of dissolution
A Dokoumetzidis, P Macheras
Pharm. Res. 14, 1122-1126 (1997)
[DOI: 10.1023/A:1012182102257] [PDF]
448K 2021-10-02
- Investigation of absorption kinetics by the phase plane method
A Dokoumetzidis, P Macheras
Pharm. Res. 15, 1262-1269 (1998)
[DOI: 10.1023/A:1011952227079] [PDF]
568K 2021-10-02
- Heterogeneous tube model for the study of small intestinal transit flow
A Kalampokis, P Argyrakis, P Macheras
Pharm. Res. 16, 87-91 (1999)
[DOI: 10.1023/A:1018874913372] [PDF]
884K 2021-10-02
- A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts
A Kalampokis, P Argyrakis, P Macheras
Pharm. Res. 16, 1764-1769 (1999)
[DOI: 10.1023/A:1018918402237] [PDF]
1020K 2021-10-02
- Fractal volume of drug distribution: It scales proportionally to body mass
V Karalis, L Claret, A Iliadis, P Macheras
Pharm. Res. 18, 1056-1060 (2001)
[DOI: 10.1023/A:1010965001162] [PDF]
208K 2021-10-02
- Drug disposition viewed in terms of the fractal volume of distribution
V Karalis, P Macheras
Pharm. Res. 19, 697-704 (2002)
[DOI: 10.1023/A:1015378701592] [PDF]
220K 2021-10-02
- The mean dissolution time depends on the dose/solubility ratio
E Rinaki, A Dokoumetzidis, P Macheras
Pharm. Res. 20, 406-408 (2003)
[DOI: 10.1023/A:1022652004114] [PDF]
72K 2021-10-02
- Novel scaled average bioequivalence limits based on GMR and variability considerations
V Karalis, M Symillides, P Macheras
Pharm. Res. 21, 1933-1942 (2004)
[DOI: 10.1023/B:PHAM.0000045249.83899.ae] [PDF]
440K 2021-10-02
- Pharmacokinetics of teicoplanin in an ICU population of children and infants
JC Lukas, G Karikas, M Gazouli, P Kalabalikis, T Hatzis, P Macheras
Pharm. Res. 21, 2064-2071 (2004)
[DOI: 10.1023/B:PHAM.0000048198.56873.d8] [PDF]
220K 2021-10-02
- Novel scaled bioequivalence limits with leveling-off properties
John Kytariolos, Vangelis Karalis, Panos Macheras, Mira Symillides
Pharm. Res. 23, 2657-2664 (2006)
[DOI: 10.1007/s11095-006-9107-1] [PDF]
240K 2021-10-02
- Bioavailability and Bioequivalence: Focus on physiological factors and variability
Vangelis Karalis, Panos Macheras, Achiel Van Peer, Vinod P. Shah
Pharm. Res. 25, 1956-1962 (2008)
[DOI: 10.1007/s11095-008-9645-9] [PDF]
140K 2021-10-02
- Physiologically-Based PK/PD Modelling of Therapeutic Macromolecules
Peter Thygesen, Panos Macheras, Achiel Van Peer
Pharm. Res. 26, 2543-2550 (2009)
[DOI: 10.1007/s11095-009-9990-3] [PDF]
224K 2021-10-02
- The Changing Face of the Rate Concept in Biopharmaceutical Sciences: From Classical to Fractal and Finally to Fractional
Aristides Dokoumetzidis, Panos Macheras
Pharm. Res. 28, 1229-1232 (2011)
[DOI: 10.1007/s11095-011-0370-4] [PDF]
156K 2021-10-02
- Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA
Vangelis Karalis, Mira Symillides, Panos Macheras
Pharm. Res. 29, 1066-1077 (2012)
[DOI: 10.1007/s11095-011-0651-y] [PDF]
544K 2021-10-02
- Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS
Georgia Charkoftaki, Aristides Dokoumetzidis, Georgia Valsami, Panos Macheras
Pharm. Res. 29, 3188-3198 (2012)
[DOI: 10.1007/s11095-012-0815-4] [PDF]
604K 2021-10-02
- An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies
Vangelis Karalis, Panos Macheras
Pharm. Res. 30, 1824-1835 (2013)
[DOI: 10.1007/s11095-013-1026-3] [PDF]
664K 2021-10-02
- A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms
Anne Zajicek, Michael J. Fossler, Jeffrey S. Barrett, Jeffrey H. Worthington, Robert Ternik, Georgia Charkoftaki, Susan Lum, Joerg Breitkreutz, Mike Baltezor, Panos Macheras, Mansoor Khan, Shreeram Agharkar, David Douglas MacLaren
AAPS J. 15, 1072-1081 (2013)
[DOI: 10.1208/s12248-013-9511-5] [PDF]
1008K 2021-10-02
- Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
Radojka M. Savic, Daniël M. Jonker, Thomas Kerbusch, Mats O. Karlsson
J. Pharmacokin. Pharmacodyn. 34, 711-726 (2007)
[DOI: 10.1007/s10928-007-9066-0] [PDF]
308K 2021-09-25
- Ring opening reactions 1. The triazinone ring opening of 2H-3,4-dihydro-as-triazino [3,4b] benzothiazol-3-one
M. D. Kazanis, P. E. Macheras
Chem. Chron. New Ser. 9, 201-205 (1980)
[PDF]
100K 2021-09-22
- Comparative bioavailability studies of four commercial nitrofurantoin products
P. E. Macheras
Chem. Chron. New Ser. 12, 63-73 (1983)
[PDF]
184K 2021-09-22
- Application of permeability-limited physiologically-based pharmacokinetic models: Part I-Digoxin Pharmacokinetics Incorporating P-Glycoprotein-Mediated Efflux
Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner, Amin Rostami-Hodjegan
J. Pharm. Sci. 102, 3145-3160 (2013)
[DOI: 10.1002/jps.23594] [PDF]
1.7M 2021-09-15
- Equivalence Lack in Digoxin Plasma Levels
John G. Wagner, Marianne Christensen, Ermelinda Sakmar, Donald Blair, James D. Yates, Park W. Willis III, Allen J. Sedman, Roger G. Stoll
J. Amer. Med. Ass. 224, 199-204 (1973)
[DOI: 10.1001/jama.1973.03220150013004] [PDF]
740K 2021-09-13
- Comparative Bioavailabilities from Truncated Blood Level Curves
E. G. Lovering, I.J. McGilveray, I. McMillan, W. Tostowaryk
J. Pharm. Sci. 64, 1521-1524 (1975)
[DOI: 10.1002/jps.2600640921] [PDF]
428K 2021-09-13
- Application of permeability-limited physiologically-based pharmacokinetic models: Part II-prediction of p-glycoprotein mediated drug-drug interactions with digoxin
Sibylle Neuhoff, Karen Rowland Yeo, Zoe Barter, Masoud Jamei, David B. Turner, Amin Rostami-Hodjegan
J. Pharm. Sci. 102, 3161-3173 (2013)
[DOI: 10.1002/jps.23607] [PDF]
864K 2021-09-13
Errata: On the heterogeneity of drug dissolution and release. (vol 17, pg 108, 2000)
P Macheras, A Dokoumetzidis
Pharm. Res. 18, 719 (2001)
[DOI: 10.1023/A:1017304632432] [PDF]
84K 2021-08-26
- The effect of HPMC - a cholesterol-lowering agent - on oral drug absorption in dogs
C Reppas, G Eleftheriou, P Macheras, M Symillides, D Greenwood, JB Dressman
Biopharm. Drug Dispos. 19, 523-530 (1998)
[DOI: 10.1002/(SICI)1099-081X(1998110)19:8<523::AID-BDD133>3.0.CO;2-J] [PDF]
160K 2021-08-26
Erratum
P Macheras
Pharm. Res. 8, 1078-1078 (1991)
[DOI: 10.1023/A:1015833830347] [PDF]
32K 2021-08-26
- Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation
K. Soulele, T. Karampelas, C. Tamvakopoulos, P. Macheras
Pharm. Res. 38, 1419-1428 (2021)
[DOI: 10.1007/s11095-021-03085-x] [PDF]
668K 2021-08-26
- Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation
Julraht Konsil, Somchit Dechasathian, David H. Mason, Jr., Ruth E. Stevens
J. Pharm. Pharmaceut. Sci. 5, 169-175 (2002)
[Source: JPPS] [PDF]
420K 2021-08-18
- Scipion PKPD: an Open-Source Platform for Biopharmaceutics, Pharmacokinetics and Pharmacodynamics Data Analysis
C. O. S. Sorzano, Y. Fonseca-Reyna, M. A. Perez Cruz-Moreno
Pharm. Res. 38 1169-1178 (2021)
[DOI: 10.1007/s11095-021-03065-1] [PDF]
1.5M 2021-07-31
60K 2021-07-29
48K 2021-07-29
80K 2021-07-29
- Digoxin Bioequivalency Reviews (76268)
(2002)
[Source: PDF] [PDF]
744K 2021-07-29
1.8M 2021-07-29
240K 2021-07-29
- Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite
K. Soulele, V. Karalis
Eur. J. Pharm. Sci. 128, 18-26 (2019)
[DOI: 10.1016/j.ejpb.2018.12.018] [PDF]
1.4M 2021-07-26
- A Population Pharmacokinetic Model That Describes Multiple Peaks Due to Enterohepatic Recirculation of Ezetimibe
Farkad Ezet, Gopal Krishna, David B. Wexler, Paul Statkevich, Teddy Kosoglou, and Vijay K. Batra,
Clinical Therapeutics 23, 871-885 (2001)
[DOI: 10.1016/S0149-2918(01)80075-8] [PDF]
960K 2021-07-25
- Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans
Nadia O. Bamfo, Chelsea Hosey-Cojocari, Leslie Z. Benet, Connie M. Remsberg
Pharm. Res. 38 1139-1156 (2021)
[DOI: 10.1007/s11095-021-03076-y] [PDF]
1000K 2021-07-23
- Fractal geometry, fractal kinetics and chaos en route to biopharmaceutical sciences
P. Macheras, Argyrakis, P. & Polymilis
Eur. J. Drug Metabolism Pharmacokinetics 21, 77-86 (1996)
[DOI: 10.1007/BF03190255] [PDF]
1.1M 2021-07-18
- A Stochastic Model Describes the Heterogeneous Pharmacokinetics of Cyclosporin
Laurent Claret, Athanassios Iliadis, and Panos Macheras
J. Pharmacokinet. Pharmacodyn. 28, 445-463 (2001)
[DOI: 10.1023/A:1012295014352] [PDF]
108K 2021-07-18
- Multivariate Statistics of Disposition Pharmacokinetic Parameters for Structurally Unrelated Drugs Used in Therapeutics
Vangelis Karalis, Anna Tsantili-Kakoulidou, and Panos Macheras
Pharm. Res. 19, 1827-1834 (2002)
[DOI: 10.1023/A:1021489323828] [PDF]
236K 2021-07-18
- Nonlinear Dynamics and Chaos Theory: Concepts and Applications Relevant to Pharmacodynamics
Aristides Dokoumetzidis, Athanassios Iliadis, and Panos Macheras
Pharm. Res. 18, 415-426 (2001)
[DOI: 10.1023/A:1011083723190] [PDF]
464K 2021-07-18
- Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts
K. Sandy Pang, Michael Weiss, and Panos Macheras
APPS J. 9, E268-E283 (2007)
[DOI: 10.1208/aapsj0902030] [PDF]
1.7M 2021-07-18
- Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples
Eleni Rinaki, Aristides Dokoumetzidis, Georgia Valsami, and Panos Macheras
Pharm. Res. 21, 1567-1572 (2004)
[DOI: 10.1023/B:PHAM.0000041450.25106.c8] [PDF]
208K 2021-07-18
- Phase 0/microdosing approaches: time for mainstream application in drug development?
Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama
Nat. Rev. Drug Discov. 19, 801-818 (2020)
[DOI: 10.1038/s41573-020-0080-x] [PDF]
2.2M 2021-07-18
- An In Vitro-In Vivo Simulation Approach for the Prediction of Bioequivalence
Marilena Vlachou and Vangelis Karalis
Materials 14, 555 (2021)
[DOI: 10.3390/ma14030555] [PDF]
4.0M 2021-07-17
- In vitro - In vivo Correlation: From Theory to Applications
Jaber Emami
J. Pharm. Pharmaceut. Sci. 9, 31-51 (2006)
[Source: JPPS] [PDF]
276K 2021-07-17
4.8M 2021-07-06
- Bioavailability of Digoxin
Trieste G. Vitti, Daniel Banes, Theodore E. Byers
New Engl. J. Med. 285, 1433-1434 (1971)
[DOI: 10.1056/nejm197112162852512] [PDF]
340K 2021-07-04
- Digoxin Bioequivalency Reviews (76268)
(2002)
[Source: PDF] [PDF]
744K 2021-06-29
- Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis-Menten elimination: analytical solution and drug exposure formula
Xiaotian Wu, Min Chen & Jun Li
J. Pharmacokin. Pharmacodyn. 48, 495-508 (2021)
[DOI: 10.1007/s10928-021-09740-5] [PDF]
648K 2021-06-25
- Bioavailability assessment: Methods to estimate total area (AUC 0-∞) and total amount excreted (Ae∞) and importance of blood and urine sampling scheme with application to digoxin
John G. Wagner and James W. Ayres
J. Pharmacokin and Biopharmac. 5, 533-557 (1977)
[DOI: 10.1007/BF01061733] [PDF]
1.3M 2021-06-19
- High-Pressure Liquid Chromatographic Assay of Theophylline in Dog Feces following Oral Administration of Sustained-Release Products
Andrew T. Chow, Patrick D. Meek, and Willian J. Jusko
J. Pharm. Sci. 82, 956-958 (1993)
[DOI: 10.1002/jps.2600820917] [PDF]
1.2M 2021-06-15
- Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial
Marija Pesic, Frank Schippers, Rob Saunders, Lyn Webster, Martin Donsbach, Thomas Stoehr
Eur. J. Clin. Pharmacol. 76, 1505-1516 (2020)
[DOI: 10.1007/s00228-020-02984-z] [PDF]
788K 2021-06-12
- Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers
Ney Carter do Carmo Borges, Rafael Barrientos Astigarraga, Carlos Eduardo Sverdloff, Bruno Carter Borges, Thais Rodrigues Paiva, Paulo Rebelo Galvinas, Ronilson Agnaldo Moreno
J. Chromatography B 879, 236-242 (2010)
[DOI: 10.1016/j.jchromb.2010.12.003] [PDF]
504K 2021-06-12
- Pharmacokinetics of Digoxin: Interpreting Bioavailability
N. Sanchez, L. B. Sheiner, H. Halkin, K. L. Melmon
Br. Med. J. 4, 132-134 (1973)
[DOI: 10.1136/bmj.4.5885.132] [PDF]
704K 2021-05-21
- Novel milk-based oral formulations: Proof of concept
Georgia Charkoftaki, John Kytariolos, Panos Macheras
Int. J. Pharm. 390, 150-159 (2010)
[DOI: 10.1016/j.ijpharm.2010.001.038] [PDF]
868K 2021-05-19
- Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
David W. Boulton, Sreeneeranj Kasichayanula, Chi Fung (Anther) Keung, Mark E. Arnold, Lisa J. Christopher, Xiaohui (Sophia) Xu, and Frank LaCreta
Br. J. Clin. Pharmacol. 75, 763-768 (2012)
[DOI: 10.1111/j.1365-2125.2012.04391.x] [PDF]
872K 2021-05-18
- Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
Jeroen Roosendaal, Hilde Rosing, and Jos H. Beijnen
Clinical Pharmacology in Drug Development 9, 552-559 (2020)
[DOI: 10.1002/cpdd.840] [PDF]
856K 2021-05-18
- Kaleo briefing on naloxone HCl
(2016)
[Source: FDA] [PDF]
3.6M 2021-05-18
- Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
Sangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, Alfin Vaz, Haihong Shi, Eric Fluhler, Eric J. Woolf, Klaas Schildknegt, Kyle Matschke, Christine Alvey, Susan Zhou, Dimitris Papadopoulos, Robert Fountaine, Didier Saur, Steven G. Terra, Lloyd Stevens, Daniel Gaunt and David L. Cutler
Clin. Transl. Sci. 11, 405-411 (2018)
[DOI: 10.1111/cts.12549] [PDF]
204K 2021-05-18
- Absorption and Disposition Kinetics of Amoxicillin in Normal Human Subjects
A. Arancibia, J. Guttmann, G. Gonzalez, and C. Gonzalez
Antimicrobial Agents and Chemotherapy 17, 199-202 (1980)
[DOI: 10.1128/AAC.17.2.199] [PDF]
744K 2021-05-18
- Fractional kinetics in multi-compartmental systems
Aristides Dokoumetzidis, Richard Magin, Panos Macheras
J. Pharmacokinet. Pharmacodyn. 37, 507-524 (2010)
[DOI: 10.1007/s10928-010-9170-4] [PDF]
736K 2021-05-12
- On the heterogeneity of drug dissolution and release
Panos Macheras & Aristides Dokoumetzidis
Pharm. Res. 17, 108-112 (2000)
[DOI: 10.1023/A:1007596709657] [PDF]
76K 2021-05-12
- The power law can describe the 'entire' drug release curvefrom HPMC-based matrix tablets: a hypothesis
E. Rinaki, G. Valsami, P. Macheras
Int. J. Pharm. 255, 199-207 (2003)
[DOI: 10.1016/S0378-5173(03)00079-6] [PDF]
132K 2021-05-12
- Analysis of Dissolution Data Using Modified Versions of Noyes-Whitney Equation and the Weibull Function
Aristides Dokoumetzidis, Vasiliki Papadopoulou & Panos Macheras
Pharm. Res. 23, 256-261 (2006)
[DOI: 10.1007/s11095-006-9093-3] [PDF]
400K 2021-05-12
- Fractional kinetics in drug absorption and disposition processes
Aristides Dokoumetzidis and Panos Macheras
J. Pharmacokinet. Pharmacodyn. 36, 165-178 (2009)
[DOI: 10.1007/s10928-009-9116-x] [PDF]
444K 2021-05-06
- A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function
Kosmas Kosmidis, Panos Argyrakis, and Panos Macheras
Pharm. Res. 20, 988-995 (2003)
[DOI: 10.1023/A:1024497920145] [PDF]
136K 2021-05-06
- Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
Eleni Rinaki, Georgia Valsami, and Panos Macheras
Pharm. Res. 20, 1917-1925 (2003)
[DOI: 10.1023/B:PHAM.0000008037.57884.11] [PDF]
136K 2021-05-06
- On the use of the Weibull function for the discernment of drug release mechanisms
Vasiliki Papadopoulou, Kosmas Kosmidis, Marilena Vlachou, Panos Macheras
Int. J. Pharm. 309, 44-50 (2006)
[DOI: 10.1016/j.ijpharm.2005.10.044] [PDF]
212K 2021-05-06
- Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug
Jonathan Brown, Caly Chien, Peter Timmins, Andrew Dennis, Walter Doll, Erik Sandefer, Richard Page, Richard E. Nettles, Li Zhu, Dennis Grasela
J. Pharm. Sci. 102, 1742-1751 (2013)
[DOI: 10.1002/jps.23476] [PDF]
480K 2021-05-04
- A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System
Aristides Dokoumetzidis, Panos Macheras
Int. J. Pharm. 321, 1-11 (2006)
[DOI: 10.1016/j.ijpharm.2006.07.011] [PDF]
368K 2021-04-25
- A non-binary biopharmaceutical classification of drugs: The ABΓ system
Panos Macheras, Vangelis Karalis
Int. J. Pharm. 464, 85-90 (2014)
[DOI: 10.1016/j.ijpharm.2014.01.022] [PDF]
972K 2021-04-24
- The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS)_ Beyond guidelines
Aggelos Charalabidis, Maria Sfouni, Christel Bergström, Panos Macheras
Int. J. Pharm. 566, 264-281 (2019)
[DOI: 10.1016/j.ijpharm.2019.05.041] [PDF]
1.8M 2021-04-24
- Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers
Konstantina Soulele, Panos Macheras, Vangelis Karalis
Biopharm. Drug Disp. 38, 407-419 (2017)
[DOI: 10.1002/bdd.2077] [PDF]
520K 2021-04-24
- Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers
K. Soulele, P. Macheras, L. Silvestro, S. Rizea Savu, V. Karalis
Eur. J. Pharm. Sci. 80, 33-42 (2015)
[DOI: 10.1016/j.ejps.2015.08.009] [PDF]
680K 2021-04-24
- The Cutoff Time Point of the Partial Area Method for Assessment of Rate of Absorption in Bioequivalence Studies
P. Macheras, Mira Symillides & Christos Reppas
Pharm. Res. 11, 831-834 (1994)
[DOI: 10.1023/A:1018921622981] [PDF]
532K 2021-04-24
532K 2021-04-24
- Gastrointestinal Drug Absorption: Is It Time to Consider Heterogeneity as Well as Homogeneity?
Panos Macheras and Panos Argyrakis
Pharm. Res. 14, 842-847 (1997)
[DOI: 10.1023/A:1012183313218] [PDF]
596K 2021-04-24
- Lost in modelling and simulation?
Kiyohiko Sugano
ADMET & DMPK 9, 75-109 (2021)
[DOI: 10.5599/admet.923] [PDF]
1.4M 2021-04-23
840K 2021-04-14
- An alternative method for the estimation of the terminal slope when a few data points are available
Aristides Dokoumetzidis, Athanassios Iliadis, and Panos Macheras
J. Pharm. Sci. 88, 557-560 (1999)
[DOI: 10.1021/js980317l] [PDF]
64K 2021-04-12
1.9M 2021-03-31
- Bioequivalence of immediate-release theophylline capsules
Marvin C. Meyer, Eric J. Jarvi, Arthur B. Straughn, Francis R. Pelsor, Roger L. Williams and Vinod P. Shah
Biopharm. Drug Disp. 20, 417-419 (1999)
[DOI: 10.1002/1099-081X(199912)20:9<417::AID-BDD205>3.0.CO;2-W] [PDF]
116K 2021-03-20
- PBPK models for the prediction of in vivo performance of oral dosage forms
Edmund S. Kostewicz, Leon Aarons, Martin Bergstrand, Michael B. Bolger, Aleksandra Galetin, Oliver Hatley, Masoud Jamei, Richard Lloyd, Xavier Pepin, Amin Rostami-Hodjegan, Erik Sjogren, Christer Tannergren, David B. Turner, Christian Wagner, Werner Weitschies, Jennifer Dressman
Eur. J. Pharm. Sci. 57, 300-321 (2014)
[DOI: 10.1016/j.ejps.2013.09.008] [PDF]
2.4M 2021-03-18
- In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration
James Butler, Bart Hens, Maria Vertzoni, Joachim Brouwers, Philippe Berben, Jennifer Dressman, Cord J. Andreas, Kerstin Julia Schaefer, James Mann, Mark McAllister, Masoud Jamei, Edmund Kostewicz, Filippos Kesisoglou, Peter Langguth, Mans Minekus, Anette Mullertz, Ronald Schilderink, Mirko Koziolek, Philipp Jedamzik, Werner Weitschies, Christos Reppas, Patrick Augustijns
Eur. J. Pharm. Biopharm. 136, 70-83 (2019)
[DOI: 10.1016/j.ejpb.2018.12.010] [PDF]
4.1M 2021-03-18
- Pharmacokinetics of tolmetin with and without concomitant administration of antacid in man
J. W. Ayres, D. J. Weidler, J. MacKichan, E. Sakmar, M. R. Hallmark, E. F. Lemanowicz & J. G. Wagner
Europ. J. Clin. Pharmacol. 12, 421-428 (1977)
[DOI: 10.1007/BF00561061] [PDF]
936K 2021-03-18
- On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches
K. Soulele, P. Macheras, V. Karalis
Pulmonary Pharmacology and Therauptics 48, 168-178 (2018)
[DOI: 10.1016/j.pupt.2017.12.002] [PDF]
720K 2021-03-18
- Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration
Hartley C. Atkinson, Ioana Stanescu, Chris Frampton, Isam I. Salem, Charles P. H. Beasleyr, Richard Robson
Clin. Drug Investig. 35, 625-632 (2015)
[DOI: 10.1007/s40261-015-0320-8] [PDF]
548K 2021-03-18
- Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients
L. van Andel, H. Rosing, Z. Zhang, L. Hughes, V. Kansra, M. Sanghvi, M. M. Tibben, A. Gebretensae, J. H. M. Schellens, J. H. Beijnen
Cancer Chemotherapy and Pharmacology 81, 39-46 (2018)
[DOI: 10.1007/s00280-017-3455-x] [PDF]
740K 2021-03-16
- Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation
H. G. Bone, M. A. Walter, M. E. Hurley, S. Epstein
Osteoporos Int. 28, 1745-1752 (2017)
[DOI: 10.1007/s00198-017-3941-3] [PDF]
432K 2021-03-16
- Mathematical Expressions of the Pharmacokinetic and Pharmacodynamic Models implemented in the PFIM software
Anne Dubois, Julie Bertrand and France Mentré
UMR738, INSERM, University Paris Diderot (2011)
[PDF]
436K 2021-03-16
- In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim
Erik Sjogren, Jan Westergren, Iain Grant, Gunilla Hanisch, Lennart Lindfors, Hans Lennernas, Bertil Abrahamsson, Christer Tannergren
Eur. J. Pharm. Sci. 49, 679-698 (2013)
[DOI: 10.1016/j.ejps.2013.05.019] [PDF]
2.7M 2021-03-15
- Pharmacokinetics of Itraconazole following Oral Administration to Normal Volunteers
Thomas C. Hardin, John R. Graybill, Richard Fetchick, R. Woestenborghs, Michael G. Rinaldi, and John G. Kuhn
Antimicrob. Agents Chemother. 32, 1310-1313 (1988)
[DOI: 10.1128/AAC.32.9.1310] [PDF]
724K 2021-03-14
- Complexity of the Basic Reproduction Number (R0)
Paul L. Delamater, Erica J. Street, Timothy F. Leslie, Y. Tony Yang, and Kathryn H. Jacobsen
Emerg. Infect. Dis. 25, 1 (2019)
[DOI: 10.3201/eid2501.171901] [PDF]
376K 2021-03-13
- Pharmacokinetics of flurbiprofen in man I. Area/dose relationships
G. J. Szpunar, K. S. Albert, G. G. Bole, J. N. Dreyfus, G. F. Lockwood and J. G. Wagner
Biopharm. Drug Disp. 8, 273-283 (1987)
[DOI: 10.1002/bdd.2510080308] [PDF]
488K 2021-03-13
- The solution of a system of differential equations occurring in the theory of radio-active transformations
H. Bateman
Proc. Cambridge Philos. Soc. Math. Phys. Sci. 15, 423-427 (1910)
[DOI: https://www.biodiversitylibrary.org/item/97262#page/487/mode/1up] or [https://archive.org/details/cbarchive_122715_solutionofasystemofdifferentia1843] [PDF]
748K 2021-03-04
- Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
Laure Wynants, Ben Van Calster, Gary S Collins, Richard D Riley, Georg Heinze, Ewoud Schuit, Marc M J Bonten, Darren L Dahly, Johanna A Damen, Thomas P A Debray, Valentijn M T de Jong, Maarten De Vos, Paula Dhiman, Maria C Haller, Michael O Harhay, Liesbet Henckaerts, Pauline Heus, Michael Kammer, Nina Kreuzberger, Anna Lohmann, Kim Luijken, Jie Ma, Glen P Martin, David J McLernon, Constanza L Andaur Navarro, Johannes B Reitsma, Jamie C Sergeant, Chunhu Shi, Nicole Skoetz, Luc J M Smits, Kym I E Snell, Matthew Sperrin, Rene Spijker, Ewout W Steyerberg, Toshihiko Takada, Ioanna Tzoulaki, Sander M J van Kuijk, Bas C T van Bussel, Iwan C C van der Horst, Florien S van Royen, Jan Y Verbakel, Christine Wallisch, Jack Wilkinson, Robert Wolff, Lotty Hooft, Karel G M Moons, Maarten van Smeden
BMJ 369, m1328 (2020)
[DOI: 10.1136/bmj.m1328] [PDF]
500K 2021-03-03
- On an Unphysical Hypothesis of Bateman Equation and its Implications for Pharmacokinetics
Panos Macheras
Pharm. Res. 36, 94 (2019)
[DOI: 10.1007/s11095-019-2633-4] [PDF]
444K 2021-03-03
- Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic
Niall P. A. S. Johnson and Juergen Mueller
Bulletin of the History of Medicine 76, 105-115 (2002)
[URL: https://www.jstor.org/stable/44446153] [PDF]
492K 2021-02-04
- Mathematical models of infectious disease transmission
Nicholas C. Grassly and Christophe Fraser
Nat. Rev. Microbiol. 6, 477-487 (2008)
[DOI: 10.1038/nrmicro1845] [PDF]
1.3M 2021-02-03
- A Brief History of R0 and a Recipe for its Calculation
J. A. P. Heesterbeek
Acta Biotheor. 50, 189-204 (2002)
[DOI: 10.1023/A:1016599411804] [PDF]
168K 2021-02-03
- An analysis of COVID-19 spread based on fractal interpolation and fractal dimension
Cristina-Maria Pacurar, Bogdan-Radu Necula
Chaos, Solitons & Fractals 139, 110073 (2020)
[DOI: 10.1016//j.chaos.2020.110073] [PDF]
2.8M 2021-01-28
- Some fractal thoughts about the COVID-19 infection outbreak
Massimo Materassi
Chaos, Solitons & Fractals: X 4, 100032 (2019)
[DOI: 10.1016/j.csfx.2020.100032] [PDF]
616K 2021-01-28
- On the use of growth models to understand epidemic outbreaks with application to COVID-19 data
Chénangnon Frédéric Tovissodé, Bruno Enagnon Lokonon, Romain Glèlè Kakai
PLOS One 15, e0240578 (2020)
[DOI: 10.1371/journal.pone.0240578] [PDF]
788K 2021-01-28
- COVID-19, flattening the curve, and Benford's law
Kang-Bok Lee, Sumin Han, Yeasung Jeong
Physica A 559, 125090 (2020)
[DOI: 10.1016/j.physa.2020.125090] [PDF]
1.4M 2021-01-27
- Notes on R0
James Holland Jones
(2007)
[PDF]
236K 2021-01-24
2.5M 2021-01-23
- Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China
Benjamin F. Maier and Dirk Brockmann
Science 368, 742-746 (2020)
[DOI: 10.1126/science.abb4557] [PDF]
952K 2021-01-16
- Fractal kinetics in drug release from finite fractal matrices
K. Kosmidis, P. Argyrakis and P. Macheras
J. Chem. Phys. 119, 6373-7377 (2003)
[DOI: 10.1063/1.1603731] [PDF]
424K 2021-01-14
- On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations
O. Diekmann, J. A. P. Heesterbeek & J. A. J. Metz
J. Math. Biol. 28, 365-382 (1990)
[DOI: 10.1007/BF00178324] [PDF]
792K 2020-12-29
- A contribution to the mathematical theory of epidemics
William Ogilvy Kermack and A. G. McKendrick
Proc. R. Soc. Lond. A 115, 700-721 (1927)
[DOI: 10.1098/rspa.1927.0118] [PDF]
2.5M 2020-12-28
- An Introduction to The Basic Reproduction Number in Mathematical Epidemiology
Antoine Perasso
ESAIM: Proceedings and Surveys 62, 123-138 (2018)
[DOI: 10.1051/proc/201862123] [PDF]
1.6M 2020-12-27
676K 2020-12-26
- Complexity of the Basic Reproduction Number (R0)
Paul L Delamater, Erica J Street, Timothy F Leslie, Y Tony Yang, Kathryn H Jacobsen
Emerg Infect Dis. 25, 1-4 (2020)
[DOI: 10.3201/eid2501.171901] [PDF]
376K 2020-12-18
- Contributions to the mathematical theory of epidemics. II. -The problem of endemicity
William Ogilvy Kermack and A. G. McKendrick
Proc. R. Soc. Lond. A 138, 55-83 (1932)
[DOI: 10.1098/rspa.1932.0171] [PDF]
3.4M 2020-12-18
- Science and Statistics
George E. P. Box
J. Am. Stat. Assoc. 71, 791-799 (1976)
[DOI: 10.2307/2286841] [PDF]
1.8M 2020-12-18
- On the dilemma of fractal or fractional kinetics in drug release studies: A comparison between Weibull and Mittag-Leffler functions
Kosmas Kosmidis, Panos Macheras
Int. J. Pharm. 543, 269-273 (2018)
[DOI: 10.1016/j.ijpharm.2018.03.060] [PDF]
484K 2020-12-18
- Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak
Sang Woo Park, Benjamin M. Bolker, David Champredon, David J. D. Earn, Michael Li, Joshua S. Weitz, Bryan T. Grenfell, and Jonathan Dushoff
J. R. Soc. Interface 17, 20200144 (2020)
[DOI: 10.1098/rsif.2020.0144] [PDF]
984K 2020-12-18
- Estimation of the basic reproduction number (R0) for the novel coronavirus disease in Sri Lanka
Samath Dharmaratne, Supun Sudaraka, Ishanya Abeyagunawardena, Kasun Manchanayake, Mahen Kothalawala and Wasantha Gunathunga
Virology J. 17, 144 (2020)
[DOI: 10.1186/s12985-020-01411-0] [PDF]
1.2M 2020-12-18
- A Fractal Approach to Heterogeneous Drug Distribution: Calcium Pharmacokinetics
P. Macheras
Pharm. Res. 13, 663-670 (1996)
[DOI: 10.1023/A:1016031129053] [PDF]
1.2M 2020-12-13
- Fractal Reaction Kinetics
Raoul Kopelman
Science 241, 1620 (1988)
[DOI: 10.1126/science.241.4873.1620] [PDF]
2.2M 2020-12-13
- Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts
Panos Macheras, Pavlos Chryssafidis
Pharm. Res. 37, 187 (2020)
[DOI: 10.1007/s11095-020-02894-w] [PDF]
1.3M 2020-12-10
Correction to: Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts
Panos Macheras, Pavlos Chryssafidis
Pharm. Res. 37, 206 (2020)
[DOI: 10.1007/s11095-020-02935-4] [PDF]
512K 2020-12-10
- Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe
Seth Flaxman, Swapnil Mishra, Axel Gandy, H. Juliette T. Unwin, Thomas A. Mellan, Helen Coupland, Charles Whittaker, Harrison Zhu, Tresnia Berah, Jeffrey W. Eaton, Melodie Monod, Imperial College COVID-19 Response Team, Azra C. Ghani, Christl A. Donnelly, Steven Riley, Michaela A. C. Vollmer, Neil M. Ferguson, Lucy C. Okell & Samir Bhatt
Nature 584, 257 (2020)
[DOI: 10.1038/s41586-020-2405-7] [PDF]
5.6M 2020-12-09
- A fractal kinetics SI model can explain the dynamics of COVID-19 epidemics
Kosmas Kosmidis, Panos Macheras
PLOS One 15, e0237304 (2020)
[DOI: 10.1371/journal.pone.0237304] [PDF]
656K 2020-11-29
- Demystifying the spreading of pandemics I: The fractal kinetics SI model quantifies the dynamics of COVID-19
Panos Macheras, Kosmas Kosmidis, Pavlos Chryssafidis
meRxiv (2020)
[DOI: 10.1101/2020.11.15.20232132] [PDF]
1.7M 2020-11-29
- A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time
Ahmad Y. Abuhelwa, David J. R. Foster, and Richard N. Upton
AAPS J. 18, 1322-1333 (2016)
[DOI: 10.1208/s12248-016-9953-7] [PDF]
1.6M 2017-08-23
- Method of residuals: Estimation of absorption and elimination rate constants having comparable values
P. Macheras
Biopharm. Drug Dispos. 8, 47-56 (1987)
[DOI: 10.1002/bdd.2510080106] [PDF]
388K 2008-02-29
Μαθήματα Εργαστηρίου Φυσικοχημείας
Εργαστήριο Φυσικοχημείας
jupiter.chem.uoa.gr